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be re-evaluated. We also studied cell cycle regulation of mammary acini development and 
cancer metastasis. We show, for the first time, that increased expression of the cell cycle 
regulator, Spy1, leads to multi-acinar mammary alveolar structures in vitro, and leads to 
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Overview of Human Mammary Gland Development and Architecture 
The mammary gland is an organ than continually undergoes rounds of proliferation, 
apoptosis, and structure remodeling during menstrual cycles, pregnancy, lactation, and then 
after weaning. This requires a strict balancing act between pro-survival and pro-apoptotic 
cues to maintain the ability to repeat the cycles of gland remodeling without developing 
cancer as evidenced by the fact that many pathways known to initiate cancer progression 
are the ones mediating normal mammary gland development (Hardy, Booth, Hendrix, 
Salomon, & Strizzi, 2010; Moses & Barcellos-Hoff, 2011; Wagner & Rui, 2008). To 
understand the progression of breast cancer, it is first important to know how the breast 
goes through normal development.  
Embryonic and prepubertal development 
Male and female mammary glands follow the same developmental pattern throughout 
intrauterine growth. During embryonic development the mammary gland develops from 
the ectoderm and mesoderm germ layers, which respectively develop into the epithelium 
and the surrounding mesenchyme. This early development of the gland relies on signaling 
between the epithelial and mesenchymal layers (Javed & Lteif, 2013). In humans, distinct 
mammary cells can be seen at 4-5 weeks gestation (Medina, 1996). At 35 days gestation 
proliferating epithelial cells form paired lines on either side of the embryo called a 
mammary crest or mammary bands. By 6 weeks gestation this crest has mostly disappeared 
except for bilateral mammary buds in the thoracic region. These buds are composed of 
layers of mammary epithelium that proliferate and extend into the mesenchyme in response 
to factors which are excreted by mesenchymal cells (Cowin & Wysolmerski, 2010; Cunha 




gestation, a distinct mammary bud can be seen invading into the underlying dermis with 
identifiable central and basal epithelial cells as well as mesenchymal cells that are 
differentiating into stromal components such as fibroblasts, adipocytes, endothelial cells, 
and smooth muscle cells. The basal cells of this primary bud are distinct from the 
surrounding basal epidermal cells by the loss of staining for cytokeratin 14 (K14), a basal 
epithelial cell marker (Javed & Lteif, 2013; Jolicoeur, Gaboury, & Oligny, 2003; Petersen 
& Polyak, 2010; Tobon & Salazar, 1974). Proliferation continues and secondary buds form 
and elongate from the primary mammary bud into the mesenchyme. At 21 weeks gestation, 
the cells of the secondary buds co-stain for K14 and K19, a luminal cell marker (Petersen 
& Polyak, 2010). Inner cells come together and form two distinct layers; inner, secretory 
epithelial cells and outer, contractile myoepithelial cells. The nipple is formed from smooth 
muscle fibers and the areola is derived from the surrounding ectoderm. These ductal 
structures continue to develop through the third trimester with approximately 15-20 
secondary branches forming (Hens & Wysolmerski, 2005; Javed & Lteif, 2013). At birth, 
infants have secretory cells that have evidence of milk in the Golgi apparatus which shows 
that lactogenic and contractile cells have differentiated enough from one another to provide 
functionality (Jolicoeur, et al., 2003).  
After birth, the breast tissue remains palpable and persists during the first 6 months 
of life. There are sex differences in size and persistence of palpable tissue with females 
having larger and more persistent nodules (McKiernan & Hull, 1981). Although there are 
no discernable differences in the cellular structures of the male and female gland up to 2 
years of life (Anbazhagan, Bartek, Monaghan, & Gusterson, 1991), there are differences 




development. By 8 months of age the lobules of the gland regress but epithelial ducts 
surrounded by myoepithelial cells are still present (Anbazhagan, et al., 1991; Javed & Lteif, 












Figure 1.1. Sketch of human embryonic mammary development. 
Mammary cells are apparent starting at around 4 weeks gestation in the mammary ridges. 
By week 6 a primary bud has formed extending into the dermis. At week 14 the primary 
bud has lost K14 staining and into the second trimester secondary buds form that are K14 
and K19 positive. Later in the third trimester the ducts that are forming are lined with inner 
K19 positive cells and outer K14 positive cells. By term, the fetus has a nipple and 
rudimentary alveolar units that are capable of milk production. After birth fat cells 
accumulate and the nipple differentiates. The inset shows a cross-section of an alveolus 
with an outer basement membrane, outer myoepithelial cells and inner luminal cells. 

































The rudimentary ductal structures of the mammary gland persist until puberty, when the 
production of sex hormones in females stimulate remodelling (Monaghan, Perusinghe, 
Cowen, & Gusterson, 1990). At this point the ductal structures begin to mature, elongate, 
and the main ducts branch off into several terminal lobular ductal units (TLDUs), each 
encased and separate from the other by stromal tissue (Cardiff & Wellings, 1999). Alveoli 
form at the end of the TLDUs and a few new alveolar structures are added after each 
menstrual cycle but the gland is still composed of mostly stromal tissue (Monaghan, et al., 
1990).  
Pregnancy, lactation, and involution 
Hormonal changes during pregnancy cause extreme remodelling of the mammary gland to 
allow for lactation after birth. Prolactin and progesterone are responsible for initiating the 
proliferation of alveoli cells during pregnancy (Brisken, 2002). Parenchymal tissue 
replaces the stromal tissue as alveoli structures are formed and cell differentiation 
predominantly happens after mid-pregnancy (Richert, Schwertfeger, Ryder, & Anderson, 
2000). In humans, the alveoli are present at puberty but become more numerous and more 
differentiated after pregnancy and progesterone signaling. 
The signaling cascades responsible for alveolar development have been primarily 
dissected in mice but these pathways are similar in humans. Progesterone signaling induces 
mammary cell differentiation during early pregnancy by activating the cytokines, 
interleukins 4 (IL-4) and 13 (IL-13). These cytokines will then activate signal transducer 
and activator of transcription 6 (STAT6) to promote cell proliferation and a commitment 




been shown to be the most highly enriched transcription factor in pubertal mouse mammary 
glands (Haricharan & Li, 2014; Khaled et al., 2007; Kouros-Mehr, Slorach, Sternlicht, & 
Werb, 2006; Oliver, Khaled, Frend, Nichols, & Watson, 2012). At this same time, during 
early pregnancy, STAT6 expression decreases and STAT5 expression increases to allow 
for generation and maintenance of alveolar progenitor cells (Yamaji et al., 2009).   
In humans, the alveolar cells become highly polarized with columnar luminal 
epithelial cells being tightly, but discontinuously, surrounded by the myoepithelial cells 
(Figure 1.1). Transcriptional targets of STAT5 include β-casein and whey acidic protein 
(Dong et al., 2010; Haricharan & Li, 2014). β-casein, a milk protein, can be seen in the 
alveoli cells after the 15th week of pregnancy and can be used as a marker of functional 
differentiation as it is not found in non-pregnant mammary glands (Suzuki et al., 2000).   
In late pregnancy and lactation, STAT5 expression, activated by prolactin mediated 
activation of prolactin receptor, is sustained and it has been shown that STAT5 expression 
is required and sufficient to induce proper alveolar morphogenesis and lactogenesis in mice 
(Cui et al., 2004; Dong, et al., 2010; Haricharan & Li, 2014; Yamaji, et al., 2009). Studies 
on lactating women showed that lactation was initiated when there was a sudden decrease 
in estrogen and progesterone but that the pituitary gland must secrete prolactin for 
successful lactation (Tyson, Khojandi, Huth, & Andreassen, 1975). Infant suckling 
stimulates the pituitary gland to release hormones and in a healthy woman the secretory 
epithelial cells will continue to produce milk until a time when weaning and involution 
occur (Tyson, et al., 1975).   
Involution is a very complex stage of mammary development which involves 




ready for future pregnancies and lactation. After weaning, the gland is remodelled once 
more and is returned to a state that is morphologically similar to the pre-pregnancy gland 
through a process known as involution. The removal of the suckling stimulus at weaning 
leads to cessation of the secretion of milk from the lumen which causes a series of signaling 
cascades which stop milk production (Rennison et al., 1993). Feedback Inhibitor of 
Lactation (FIL), identified as a subset of milk proteins found in the whey of many different 
mammals’ milk, accumulates in the lumen of the alveoli when milk is not expelled by 
suckling and begins the involution cascade. FIL works by changing the structure of the 
Golgi apparatus and endoplasmic reticulum to inhibit protein trafficking and protein 
secretion which allows the proteins to accumulate in the cell (Rennison, et al., 1993; Wilde, 
Addey, & Knight, 1989). In one study to determine the affect of FIL on cells, after only 
one hour of adding FIL to cells, the Golgi apparatus no longer exhibited perinuclear 
localization but was diffused throughout the cell (Rennison, et al., 1993).  In this same 
study the endoplasmic reticulum was also disrupted but both processes were reversible with 
the removal of FIL.    
The major regulator of apoptosis during involution is STAT3, which is activated 
by phosphorylation of transforming growth factor β3, as seen in a study where deletion of 
STAT3 blocked mammary gland involution (Haricharan & Li, 2014; Humphreys et al., 
2002; Nguyen & Pollard, 2000). As the cells become apoptotic, they start to lose their tight 
junction due to a cleavage of  E-cadherin and translocation of β-catenin to the nucleus and 
the epithelial cells of the alveoli become phagocytic to begin clearing of the dead cells 




In the second phase of involution, the gland begins major remodeling and 
proteolysis occurs to remove components of the extracellular matrix (ECM). These late 
stages of involution are marked by increasing expression of certain proteases, such as 
plasminogen which activates matrix metalloproteinase (MMP) family members (Lamote, 
Meyer, Massart-Leen, & Burvenich, 2004). Once the MMPs become active and start 
removing the basement membrane, cells which did not die in the first phase of involution 
will now become apoptotic and the involution will become irreversible (Watson, 2006). 
The MMPs are kept inactive until this later stage of involution by tissue inhibitor of 
metalloproteinases to ensure the first phase of involution is reversible but once MMPs are 
actively clearing the gland the involution is irreversible (Fata et al., 2001).  
The final stages of involution include recruitment of macrophages to clear the 
secretory structures, deposition of ECM proteins by fibroblasts, and adipocyte 
differentiation, all of which will bring the gland back to the stage resembling pre-pregnancy 
(Flanders & Wakefield, 2009; O'Brien et al., 2010).     
Role of stem cells in development 
Although massive rounds of apoptosis happen during involution, the mammary gland will 
retain the ability to reconstitute and undergo subsequent rounds of lactation. Regenerative 
capacity is dictated by the presence of multipotent adult mammary stem cells (MaSCs), 
cells which can differentiate into the different lineages needed for the gland to function. 
MaSCs were first described, in 1959, as a population of cells capable of self-renewing and 
reconstituting the gland upon transplantation (Deome, Faulkin, Bern, & Blair, 1959). 
MaSCs have impressive potency and even a single stem cell has the capacity to reconstitute 




There are still a lot of unanswered question regarding MaSCs but the current most 
accepted model of mammary cell hierarchy can be summarized as follows: embryonic 
multipotent stem cells can self-renew or give rise to unipotent basal and multipotent 
luminal progenitors. Although hormone signaling is critical for mammary epithelial 
mitosis, MaSCs lack expression of estrogen receptor (ER), progesterone receptor, human 
epidermal growth factor receptor 2, and interestingly express high levels of epidermal 
growth factor receptor, K5/6, and the myoepithelial marker p63 (Boecker et al., 2018; 
Memmi et al., 2015). These basal and luminal progenitors can self-renew or 
asymmetrically divide to give rise to basal cells and ductal or alveolar cells, respectively. 
Ductal and alveolar cells can be ER positive or negative. An alternative model suggests 
there are, in fact, separate unipotent ductal and alveolar progenitors and not just luminal 
progenitors that can differentiate into the separate lineages (C. O. dos Santos et al., 2013; 
E. Lee, Piranlioglu, Wicha, & Korkaya, 2019; Lloyd-Lewis, Harris, Watson, & Davis, 
2017; Medina, 1996; Visvader, 2009). 
With the advance in techniques of tissue dissociation and fluorescence activated 
cell sorting, cell surface antigens corresponding to MaSCs began to be described 
(Sreekumar, Roarty, & Rosen, 2015; Stingl, Eaves, Zandieh, & Emerman, 2001). Although 
these methods have greatly improved the way that stem cells can be studied, there is a lot 
of heterogeneity in cell surface marker expression during development which contributes 
to conflicting data. The consensus for human MaSCs is that the most primitive basal cells 
have the highest expression levels of  cluster of differentiation (CD) 49f (α6-integrin) and 
low expression levels of epithelial cell adhesion molecule (EpCAM). Luminal cells have 




2006; Visvader, 2009). There are bipotent human mammary epithelial progenitors that also 
stain positive for CD49f and EpCAM but do not stain for mucin1, a protein that regulates 
pluripotent stem cells (Hikita, Kosik, Clegg, & Bamdad, 2008; Stingl, et al., 2006). 
Staining of human breast tissue for these markers found that only cells contained in the 
ducts had the capacity for self-renewal, clonal growth, and bi-potency and a population of 
cells expressing both keratins K19 and K14 was only present in the ducts (Villadsen et al., 
2007). In addition to cell surface markers, the expression of high aldehyde dehydrogenase 
1 activity has been described in cells possessing stem cell properties including the ability 
to reconstitute a functional gland (Ginestier et al., 2007; Kuperwasser et al., 2004; 
Visvader, 2009). In summary, stem cells regulate the ability of the mammary gland to 
undergo multiple rounds of pregnancy, lactation, and involution when the alveolar 
structures are no longer need. Stem cells are critical for maintaining normal function of the 
gland but required strict regulation to avoid continuous activation of the cell cycle. 
Cell cycle regulation  
Another important level of regulation during mammary gland development is the cell cycle. 
The cell cycle is a ubiquitous process whereby cells are guided by various signals to make 
choices that determine their fate, for example, divide to form two daughter cells or exit the 
cycle to enter a resting state. The cell cycle is divided into phases named G1, S, G2, M and 
a phase named G0 whereby a cell has exited the cell cycle and remains dormant or quiescent 
until further cell division is required (Nakamura-Ishizu, Takizawa, & Suda, 2014; Pardee, 
1974). G1 is the first “gap” phase whereby cells either decide to exit the cycle in 
unfavourable conditions or commit to divide and proceed to increase in size, produce 




phase (Loddo et al., 2009). In the next “gap” phase, G2, cells double in size in preparation 
for mitosis, M phase, where the cell will split into two equal daughter cells (Schafer, 1998). 
Cells will then make the decision to exit the cycle into G0 to remain until needed, terminally 
differentiate, senesce (cells irreversible cease to divide), or progress through G1 and enter 
the cell cycle again (Loddo, et al., 2009; Stoeber et al., 2001). 
 Positive cell cycle regulation is mainly through the CDKs which were first 
characterized in yeast, in which a single CDK (Cdc28 in budding yeast and Cdc2 in fission 
yeast)  was found to regulate the cell cycle through interactions with cyclin (so named 
because of their cyclic expression during the cell cycle) partners (Lim & Kaldis, 2013; 
Nurse & Thuriaux, 1980; Reed, Ferguson, & Groppe, 1982). In mammals there are many 
CDKs and cyclins and the mammalian cell cycle is generally seen to be regulated by the 
CDK4/6/Cyclin D complex in G1, CDK2/Cyclin E/A complex at G1/S transition, and 
CDK1/Cyclin B complex at G2/M (Schafer, 1998). There are currently 21 known CDKs 
(Axtman, Drewry, & Wells, 2019) characterized by a conserved catalytic core which 
includes an adenosine triphosphate (ATP)-binding pocket, PSTAIRE-like cyclin-binding 
sequence motif, and a T-loop activating motif (Lim & Kaldis, 2013). These elements work 
together as the mechanism of CDK activation where cyclins or cyclin-like proteins 
associate with the CDKS at the PSTAIRE domain which displaces the T-loop and exposes 
the substrate binding site, meanwhile the ATP-binding or active site is made ready for the 
activating phosphorylation (Lim & Kaldis, 2013; Pavletich, 1999). CDKs are also 
regulated by phosphorylation at specific threonine (T) and tyrosine (Y) sites, which vary 
for the different CDKs, to activate or inhibit the activity of the CDK (Schafer, 1998). For 




phosphorylated at the inhibitory sites T14 and/or Y15 by Wee1, after cyclin binding, 
followed by phosphorylation at the stimulatory site T160 by CDK activating kinase 
(CDK7/Cyclin H) but this complex remains in an inactive state until T14 and Y15 are 
dephosphorylated by the phosphatase Cdc25A (Bartova, Otyepka, Kriz, & Koca, 2004; 
Rudolph, Epstein, Parker, & Eckstein, 2001; Stevenson, Deal, Hagopian, & Lew, 2002).  
 Although traditional cyclins require these phosphorylation and dephosphorylation 
events to activate the CDK complex, Speedy or Spy1 encoded by the SPDYA gene, which 
has no homology with the cyclins, can activate CDK1 and CDK2 independently of 
phosphorylation by CDK activating kinase (Cheng, Gerry, Kaldis, & Solomon, 2005; 
Cheng, Xiong, Ferrell, & Solomon, 2005; Karaiskou et al., 2001). Spy1 was first isolated 
from a Xenopus cDNA library screen (as xSpy1) in rad1 deficient yeast (S. pombe) as a 
cell cycle regulator that could overcome the G2/M checkpoint after ultra violet (UV) 
damage (Lenormand, Dellinger, Knudsen, Subramani, & Donoghue, 1999). In an 
independent screen for regulators of meiotic maturation in xenopus oocytes, Speedy 
proteins were identified as enhancing meiotic maturation of oocytes as compared to 
progesterone (Ferby, Blazquez, Palmer, Eritja, & Nebreda, 1999). In this study the proteins 
were referred to as rapid inducer of G2/M progression in oocytes proteins (RINGO).   
A human homolog to xSpy1, Spy1, was identified using a testis cDNA library and 
was found to be expressed at low levels in various tissues but highly expressed in the testis 
(Cheng, Xiong, et al., 2005; Porter et al., 2002). Specifically in mammary tissue, Spy1 
protein was found to be localized to epithelial cells with weak or absent expression in the 
myoepithelial cells and adipose tissue (Golipour et al., 2008). Protein and mRNA analysis 




higher expression in early pregnancy, expression levels decreasing for late pregnancy and 
lactation, and then levels increasing again during involution. In this same study, treatment 
with mitogen-activated protein kinase (MAPK) inhibitors significantly decreased Spy1. 
Inducing c-Myc expression in cells elevated Spy1 expression suggesting Spy1 regulation 
is downstream of both MAPK and c-Myc (Golipour, et al., 2008). Spy1 not only has the 
ability to activate CDKs but through the Spy1/CDK2 complex, is also able to override cell 
cycle checkpoints (McAndrew, Gastwirt, Meyer, Porter, & Donoghue, 2007; Porter, Kong-
Beltran, & Donoghue, 2003).  
Healthy cells have natural checkpoints or restriction points at specific times in the 
cell cycle to ensure they won’t divide when there are unfavorable conditions like 
insufficient nutrients or DNA damage. These checkpoints are defined as “a biochemical 
pathway that ensures dependence of one process upon another process that is otherwise 
biochemically unrelated” (Elledge, 1996; Schafer, 1998). For example, an early cell cycle 
checkpoint is the amount of growth factors. In the presence of sufficient growth factors, 
cells in G0 can be stimulated into G1 and progress through early G1 where the checkpoint 
is the timing in which removal of growth factors no longer halts the cell cycle and the cell 
will continue into S phase in the absence of sufficient growth factors (Schafer, 1998). In 
G1 and G2 there are DNA damage checkpoints that will activate DNA damage repair or 
cell death pathways if DNA cannot be repaired. 
Different types of genes will regulate biological checkpoints to halt the cell cycle 
if necessary. One of the most well known “guardians” of these checkpoints, is the tumour 
suppressor p53. The G1 DNA damage checkpoint was first reported to be completely 




response to DNA damaging agents (Little, Nagasawa, Keng, Yu, & Li, 1995). However 
other later studies were able to show p53-independent G1 checkpoint activation indicating 
p53 is not always required for this checkpoint (Deeds, Teodorescu, Chu, Yu, & Chen, 2003; 
Vaziri & Faller, 1997). Upregulation of p53 induces transcription of many genes, including 
the cyclin dependent kinase (CDK) inhibitors, of which there are two families; inhibitors 
of CDK4 (INK4) and Cip/Kip members. The INK4 family contains p16INK4a, p15INK4b, 
p18INK4c, and p19INK4d which specifically inhibit CDK4/6 by competing with D-type 
cyclins to prevent binding (Canepa et al., 2007). The Cip/Kip family includes p21Cip1, 
p27Kip1, and p57Kip2 and can inhibit a wide range of CDKs by their ability to directly bind 
to both the CDK alone and when they are in complex with cyclins (Evans, Rosenthal, 
Youngblom, Distel, & Hunt, 1983), and CDKs (Sherr & Roberts, 1999).  
Previous research has shown that the CDK2/Spy1 complex is able to phosphorylate 
p27 which leads to its degradation (McAndrew, et al., 2007; Porter, et al., 2003). This is 
one important mechanism of Spy1 mediated regulation of the cell cycle. Proper cell cycle 
regulation is key in maintaining normal function of the mammary gland and because Spy1 
is able to enhance cell cycle progression independently of the cell’s natural inhibitory 
mechanisms, it is crucial to further determine how Spy1 is regulating normal mammary 
morphogenesis and how altered Spy1 expression can affect normal gland development.    
Comparison of human and mouse development 
What we know about the distinct structures of human embryonic and pubertal mammary 
development has mostly been obtained from tissues taken during necropsies but when 
studying the distinct stages of pregnancy, lactation, and involution, human tissue samples 




Monaghan, et al., 1990; Tobon & Salazar, 1974). For obvious reasons, gene manipulation 
in the human breast in vivo is not performed so animal models, primarily mouse, have been 
developed to study gland development as well as which genes and hormones are essential. 
Both human and mouse glands develop from the same ectodermal layer which forms 
distinct milk buds; 1 pair in humans and 5 pairs in mice (Cardiff & Wellings, 1999). These 
buds will later become the mature mammary glands.  The mouse gland has a persisting fat 
pad that remains throughout development whereas the human gland has immature fat cells 
early in development but a distinct fat pad is not found later on even though there is an 
abundance of fat cells (Anbazhagan, et al., 1991; Cardiff & Wellings, 1999; Javed & Lteif, 
2013). The major difference in gland structure between species in the terminal functional 
units of the gland which is mostly hormone regulated. The human gland has a complex 
ductal system with five to ten main ducts extending from the nipple and each duct contains 
a separate lobe with its own ductal system and collagenous stromal tissue with the 
functional unit being referred to as a TLDU. The mouse gland contains a single primary 
duct that branches into five to ten secondary ducts with terminal end buds (TEBs) or 
“lobulo-alveolar” units. (Cardiff & Wellings, 1999; Richert, et al., 2000). Even though 
there are some structural differences in the development of the gland, the alveolar units are 
very similar and so mice are a very useful model for investigating the signaling pathways 
involved in assuring that the alveoli function properly during lactation and then are cleared 
during involution.  
Mammary Gland Microenvironment  
The mammary gland can be compartmentalized into the epithelium and the stroma, the 




include fibroblasts, adipocytes, and immune cells (Weigelt & Bissell, 2008) (Figure 1.2). 
Together these components make up the mammary microenvironment. The 
microenvironment plays in integral part of normal mammary development as well as 














Figure 1.2. The mammary microenvironment.  
The mature alveolus is made up of epithelial cells surrounded by contractile, endothelial 
cells. These structures are held together by a thin basement membrane. In the surrounding 
microenvironment, the breast has many adipose cells, immune cells, fibroblasts, ECM 
components, and blood vessels. Each contributing to the signaling to signaling cues 









Characteristics of the mammary ECM 
The ECM is important in maintaining the structural integrity of the gland as well as 
providing regulatory signals to the epithelium (Schedin & Keely, 2011). ECM fibers 
assemble in non-random orientation to provide matrix support and adhesion sites to the 
surrounding cells. The major structural component of the ECM is fibrillar collagen which 
provides ligand binding sites for many receptors as well the structural support (Maller, 
Martinson, & Schedin, 2010). The basal lamina or basement membrane is a highly 
organized compartment of the ECM that separates the epithelial cells from the less 
structured, collagen I-rich ECM compartments and is composed of collagen IV, laminins, 
entactin, and proteoglycans (Monaghan, Warburton, Perusinghe, & Rudland, 1983; 
Schedin & Keely, 2011). This structural regulation of the ECM is maintained by growth 
factors which signal to fibroblasts that will deposit stroma and arrange collagen (Schedin 
& Keely, 2011).  
Cell-ECM interactions play a role in almost every process of mammary gland 
development and maintenance (Muschler & Streuli, 2010). For example, the laminins, 
laminin-1 in particular, cooperate with lactogenic hormones to promote differentiation of 
mammary cells, inducing expression of β-casein, and maintain proper cell polarity of 
epithelial cells (Alcaraz et al., 2008; Bissell & Bilder, 2003; Slade, Coope, Gomm, & 
Coombes, 1999; Streuli et al., 1995). Laminin-5 (or laminin-V) binds to its receptors to 
allow for the branching of mammary cells as was shown in three-dimensional (3D) culture 
assays where normal breast cells did not show the branching morphogenesis when laminin-




One of the other major regulators of cell-ECM interactions are the integrins which 
are cell surface receptors for various components of the ECM, including vitronectin, 
fibronectin, and collagen (Ganguly, Pal, Moulik, & Chatterjee, 2013). There are 18 α 
subunits and 8 β subunits that can form 24 different heterodimer pairs that are capable of 
binding to different substrates (Takada, Ye, & Simon, 2007). The possible integrin subunits 
and some of their corresponding ligands are described in Table 1.1. It is important to note 
that this is not an exhaustive list of integrin ligands and others have been described (Takada, 




















α1β1 Laminin, collagen, Semaphorin 7A 
α2β1 Laminin, collagen, Echovirus 1, tenascin 
α3β1 Laminin, thrombospondin, vascular endothelial growth factor (VEGF-A) 
α4β1 mucosal vascular addressin cell adhesion molecule, Vascular cell adhesion 
molecule-1 (VCAM-1), fibronectin 
α5β1 Fibronectin, fibrillin, thrombospondin,  
α6β1 Laminin, thrombospondin 
α7β1 Laminin 
α8β1 fibronectin, nephronectin 




αVβ1 Laminin, fibronectin, osteopontin, vitronectin 
αLβ2 Intercellular Adhesion Molecule (ICAM)-1-5s 
αMβ2 ICAM-2, fibrinogen, heparin 
αXβ2 ICAM-1, iC3b, fibrinogen, heparin, factor X  
αDβ2 VCAM-1, vitronectin, plasminogen 




αVβ3 Fibrinogen, vitronectin, von Willebrand Factor, thrombospondin, fibrillin, 
tenascin, platelet endothelial cell adhesion molecule, fibronectin, 
osteopontin, MMP, VEFG-A 
α6β4 Laminin 
αVβ5 Osteopontin, thrombospondin, vitronectin, fibronectin, fibrinogen 
αVβ6 fibronectin, osteopontin, fibrillin, tenascin, vitronectin 




Table 1.1 Integrins and their ligands.  
A summary of possible intergrin subunit and their main ligands. Adapted with permission. 














The activation of integrins is very complex and been shown to be dependent on 
talin binding to the cytoplasmic tail of the integrin (Chinthalapudi, Rangarajan, & Izard, 
2018). Ras associated protein 1 (RAP1), a small guanosine triphosphate hydrolase 
(GTPase), and phosphatidylinositol 4,5-bisphosphate (PIP2) synergize to promote talin 
activation of integrins (Bromberger, Zhu, Klapproth, Qin, & Moser, 2019). RAP1 also 
regulates E-cadherin mediated cell-cell adhesion as seen in ovarian carcinoma cells where 
RAP1 inhibition led to a loss of E-cadherin from the cell surface (Price et al., 2004). RAP1 
is regulated through extracellular signaling by cyclic adenosine monophosphate and 
calcium, among others (Bos, de Rooij, & Reedquist, 2001).   
Downstream signaling of integrins includes many pathways, mostly through focal 
adhesion kinase (FAK) activation, which can then activate other kinases and regulate 








Figure 1.3.Integrin signaling pathways. 
Integrin activation leads to signaling in a multitude of pathways which are involved in 
many cell processes essential for mammary development. Activation of integrins can, in 
turn, activate FAK which will signal downsteam to survival, migration, adhesion, polarity, 
and differentiation pathways such as extracellular-signal-regulated kinase (ERK), RhoA 






Immune response in the mammary gland 
The immune system plays a role in all bodily organs but is especially influential in the 
mammary gland during gland morphogenesis as the changing stroma is populated by 
immune cells. The immune system is a double-edged sword of the mammary gland. It can 
protect the gland from infection and promote normal morphogenesis but when held in a 
chronic state of activation can lead to transformation and cancer progression. The main 
immune cells in the mammary gland are macrophages, T lymphocytes, eosinophils and 
mast cells (Need, Atashgaran, Ingman, & Dasari, 2014). These immune cells are influenced 
by hormonal changes in both mice and humans. In the human gland, ERα down-regulates 
the nuclear factor-kappa B (NF-κB) pathway to stimulate macrophage cells (Murphy, 
Guyre, & Pioli, 2010; Need, et al., 2014) which are necessary for both proper ductal 
branching during puberty and also clearing of apoptotic tissue during involution (Gouon-
Evans, Rothenberg, & Pollard, 2000; Masso-Welch, Merhige, Veeranki, & Kuo, 2012). 
Fibroblasts, macrophages, mast cells, and eosinophils, but not basophils, T, or B cells, are 
found in the stroma immediately surrounding the developing TEBs of pubertal mouse 
glands suggesting a role in maintaining stem cells (Coussens & Pollard, 2011). Later in 
development, when branching is not occurring, the macrophages are found within the 
adipose tissue and not surrounding the ducts (Coussens & Pollard, 2011). Macrophages are 
critical for the stem cell niche, as mice depleted of these cells had significantly reduced 
mammary gland regenerative capacity when transplanted with mammary stem cells 
(Gyorki, Asselin-Labat, van Rooijen, Lindeman, & Visvader, 2009). Both innate and 
adaptive immune cell populations are found in high abundance during alveolar 




into the milk to provide antimicrobial properties to the milk and antibodies which transfer 
immune protection to nursing young (Atabai, Sheppard, & Werb, 2007; Coussens & 
Pollard, 2011). 
  Chemokines and cytokines are other immune components that are secreted by the 
different cell types, including epithelial cells, fibroblast, adipocytes, and immune cells. 
These secreted factors play many roles in the mammary gland such as promoting (IL-1, IL-
6, IL-8, tumour necrosis factor-alpha (TNFα)) and down-regulating inflammation (IL-10), 
and enhancing tissue growth by recruiting macrophages and eosinophils when needed 
(Coussens & Pollard, 2011; Need, et al., 2014; Riollet, Rainard, & Poutrel, 2000). IL-4 and 
IL-13, through downstream STAT6 signaling, are important regulators of mammary cell 
differentiation as shown in mouse knockout experiments where alveolar morphogenesis is 
reduced in both STAT6–/– and IL-4–/–/IL-13–/– animals (Khaled, et al., 2007).   
In summary, immune response is not only for protection against xenobiotics, but is 
a regulation that takes place throughout normal development and is essential for a normal 
functioning mammary gland.  
Breast Cancer  
According to GLOBOCAN statistics, in 2018 cancer killed a combined total of over 9 
million people worldwide (Bray et al., 2018). In over 100 countries breast cancer was the 
leading cause of cancer mortality for women, accounting for about 15% of cancer deaths 
(Bray, et al., 2018).  In Canada, breast cancer is the second deadliest cancer, behind lung 
cancer, and it is estimated that in 2019 approximately 5000 Canadian women will have 
died from this disease (Canadian Cancer Statistics 2019). Males represent only about 1% 




development between the sexes (Liu, Johnson, & Ma, 2018). Historically, survival rates 
for breast and other cancers were low, but after many advances in detection and treatment 
of primary breast tumours the survival rate has risen dramatically. Today, most deaths are 
due to tumours that metastasize to vital organs for which there is currently no cure. The 
drastic difference in the survival rates between metastatic and non-metastatic breast cancer 
makes it necessary to improve treatment options for those with metastases.  
Breast cancer subtypes 
Breast cancer is a multifaceted disease and can be classified into molecular subtypes which, 
with the advancements in transcriptomic and proteomic assays, are continually being 
further divided based on characteristics such as molecular signatures, morphological 
differences, and treatment response. The subgroups found within the major subtypes are 
continually being redefined (Dai et al., 2015; Russnes, Lingjaerde, Borresen-Dale, & 
Caldas, 2017) and it is impossible to provide a comprehensive list of clusters that have 
been discovered but it is important to note that there is heterogeneity within the subtypes. 
The major subtypes are classified as Luminal A and B, human epidermal growth factor 
receptor 2 (HER2)-enriched, basal like, claudin-low, and normal-like (Sarmiento-Salinas 
et al., 2019; Visvader, 2009). These subtypes are divided based on cell receptor status (ER, 
PR, and HER2) and abundance of proliferating cells (through Ki67 antigen staining within 
the nucleus) within the tumour sample. Luminal A can be summarized as ER+/PR+/HER2-
/Ki67-, grade 1/2 disease, good patient outcome. Luminal B is more proliferative with 
ER+/PR+/HER2-or+/Ki67+ signature, grade 2/3 disease, and intermediate patient 
outcome. Luminal A and B cancer cells have genetic signatures most similar to 




disease with poor patient outcome. These cancers are proposed to have been derived from 
luminal progenitor cells (Visvader, 2009). Basal breast cancer is ER-/PR-/HER2- with 
grade 3 disease and poor outcome. It has been shown that these basal cancer cells are very 
similar in genetic profile to luminal progenitor cells (Visvader, 2009). Claudin-low breast 
cancer are ER-/PR-/HER2-, claudin-low, and express low levels of cell adhesion and 
luminal genes. Their gene signature most closely resembles mesenchymal cell signatures 
(Malhotra, Zhao, Band, & Band, 2010; Visvader, 2009). Normal-like breast cancer is 
ER+/PR+/HER2+/Ki67-, can be grade 1/2/3 and has intermediate patient outcome (Dai, et 
al., 2015; Russnes, et al., 2017). Cells from normal-like cancer have gene signatures that 
heavily overlap with MaSCs (Visvader, 2009).  
Breast cancers have also been subtyped based on morphology and staging as 
follows: Ductal carcinoma in situ develops inside of the ducts and is not invasive but has 
high potential to become invasive; invasive or infiltrating breast cancer, which is divided 
into invasive ductal carcinoma and invasive lobular carcinoma, has cancer cells that invade 
outside of the normal ducts and lobules into the surrounding stroma; metastatic breast 
cancers have cancer cells that have spread to other organs of the body such as lymph nodes, 
lung, bone, brain, and liver; inflammatory breast cancer causes edema of the breast and the 
cancer cells do not form typical tumours thus making it hard to identify on mammograms 
(Feng et al., 2018; Malhotra, et al., 2010).   
Breast cancer progression 
As necessary as the stem cells are for normal mammary gland development and function, 




cell population is needed to keep the balance between regenerating the gland as needed but 
exiting the cell cycle when growth is no longer required.     
There are three central models of breast cancer propagation that have been proposed 
but should not be taken to be mutually exclusive as none of the models can accurately 
explain findings from all tumours (Shackleton, 2010). First, the cancer stem cell (CSC) 
model proposes that tumorigenic stem cells stably generate more tumorigenic clones of 
themselves but also generate phenotypically different non-tumorigenic cells. In this theory, 
the cancer initiating cells are rare cells that are distinct from the bulk tumour and can 
potentially lose their tumorigenicity through asymmetric division (Dick, 2008; Kreso & 
Dick, 2014; Shackleton, 2010). The clonal evolution model is based on cells acquiring 
genetic mutations that give them a malignant advantage over other cells. The genetic 
heterogeneity of tumours suggests divergent clones can arise from cells within the tumour 
bulk and can help explain why a subset of tumour cells acquire drug resistance (Nowell, 
1976; Shackleton, 2010; Visvader, 2009). The final model is termed the interconversion 
model (or phenotypic plasticity model) and proposes that cells can go back and forth 
between malignant and quiescent states. The plasticity of cells is well documented and so 
it is possible that the malignant potential of cells in not necessarily intrinsic, as the CSC 
model suggests (Gupta, Chaffer, & Weinberg, 2009; Shackleton, 2010). These models are 
depicted in Figure 1.4.    
Whether stem cells initiate cancer or cancer has already been initiated when the 
cells become stem-like, studies have be able to isolate different stem cells from the different 
classified breast cancer subtypes lending to the theory that different stem-cells drive 





Figure 1.4. Different models of tumor heterogeneity. 
(A) Clonal evolution or stochastic model suggests that all cells are capable of renewal and 




(CSC) model tumour contain a heterogenous population of cells organized in a hierarchy 
where only a small subset of CSCs has the ability to self renew and generate a large 
population of differentiated daughter cells by unidirectional conversion. (C) 
Interconversion or phenotype plasticity model suggests that differentiated cells can be 
return to an undifferentiated state or stem cell-like state given the appropriate stimulus. 
Tumour heterogeneity is achieved through this bidirectional conversion between CSC on 




















Some mechanisms of breast cancer stem cell (BCSC) regulation are depicted in 
Figure 1.5. These are pathways that regulate MaSCs in the normal gland but become 
deregulated in tumourigenesis (Czerwinska & Kaminska, 2015; Sin & Lim, 2017). For 
example, in breast cancer, Wnt pathway inhibitors, Wnt inhibitory factor1, Secreted 
Frizzled-Related Protein 1, and Dickkopf-related protein 1 are often methylated and 
silenced in breast cancer which leads to aberrant activation of the Wnt pathway and 
acquisition of a stem cell phenotype (Klarmann, Decker, & Farrar, 2008).      
BCSCs are also implicated in resistance to breast caner treatment because of their 
enhanced DNA repair mechanisms, their lengthened cell cycle, and increased activity of 
membrane transporters which can evade chemotherapies designed to target fast growing 
cells (Al-Hajj, Wicha, Benito-Hernandez, Morrison, & Clarke, 2003; Czerwinska & 






Figure 1.5. Schematic representation of signaling pathways that control maintenance of 
BCSCs. 
In the presence of Wnt ligand, β-catenin is stabilised, translocates to the nucleus and 
induces gene expression by binding to transcription factors such as T-cell factor/lymphoid 
enhancer-binding factor (TCF/LEF). In Notch signaling, ligand binding causes the receptor 
fragment to be cleaved by TACE (TNF-α ADAM metalloprotease converting enzyme) then 
γ-secretase to create NICD (Notch intracellular domain), which forms a complex with 
transcription factors RBPJ and CSL (CBF1/Suppressor of Hairless/LAG-1), and activates 
the expression of target genes. Sonic Hedgehog (SHH) binds to Patched (PTCH), which 
constitutively represses Hh pathway activity through its interaction with a transmembrane 
protein Smoothened (SMO). Shh-bound PTCH activates SMO and activated SMO releases 




translocates into the cell nucleus to regulate gene expression. Activation of TGF-β type I 
and type II receptors activates the receptor kinases and phosphorylation of the R-Smads, 























Cell cycle regulation in breast cancer 
Malignancy occurs when cells gain the ability to overcome the natural restriction and 
checkpoints in the cell cycle that are meant to prevent uncontrolled cell division (Schafer, 
1998). One protein able to overcome these restriction points is Spy1. It is able to override 
the G1/S cell cycle checkpoint in the presence of p21, which is a potent inhibitor of 
Cyclin/CDK2 complexes, CDK2/Cyclin A in particular, at this checkpoint (Karaiskou, et 
al., 2001; Sherr & Roberts, 1999). It is proposed that in the presence of Spy1, p21 has a 
lower binding affinity to CDK1 and thus is unable to inhibit the complex (Karaiskou, et 
al., 2001). Spy1 was also shown to be able to overcome p27 inhibition by directly binding 
to p27 and CDK2 and this resulting complex is able to phosphorylate p27 on T187 to target 
it for degradation and prevent it from inducing cell cycle arrest (Porter, et al., 2003). It was 
also determined that Spy1 could activate CDK2 in the presence of genotoxic stress to 
override the DNA damage response which may lead to tumorigenesis (E. A. Barnes, Porter, 
Lenormand, Dellinger, & Donoghue, 2003).  
Specifically in mammary tissue, HC11 mammary cells expressing exogenous Spy1 
were shown to increase the rate of lobular development in a mouse mammary gland 
transplant model and by 13 weeks post transplant, there were large, invasive tumours in 
83% of mice (Golipour, et al., 2008). Spy1 was found to be upregulated in epithelial cells 
isolated from breast-invasive ductal carcinoma samples, invasive lobular carcinoma 
tumours, and breast cancer cell lines (Al Sorkhy et al., 2012; Zucchi et al., 2004). Further 
investigation found that the Spy1 chromosomal loci (2p23.2) may be a site for increased 
risk of breast cancer in women under the age of 50 (Arason et al., 2010; Smith et al., 2006). 




resistance to tamoxifen (a drug used to treat ER+ breast cancer) through activation of the 
ERK1/2 pathway. This activation was independent of mitogen-activated protein kinase 
kinase (MEK) activity but dependent on Ras and Raf activation (Ferraiuolo, Tubman, 
Sinha, Hamm, & Porter, 2017). Spy1 has also been implicated in the progression of 
colorectal cancer, glioma, liver cancer, ovarian cancer, and neuroblastoma (Q. Jin et al., 
2018; Ke et al., 2009; Lu et al., 2016; Lubanska et al., 2014; Lubanska & Porter, 2014).  
Conventional cyclins also play a role in breast cancer processes. In a transgenic 
mouse model of Cyclin-D1 overexpression, 75% of mice formed adenocarcinoma after 18 
months, suggesting its oncogenic potential. This model suggested a weak oncogenic 
potential based on the long latency of tumour formation, however in humans it is 
overexpressed in 30-60% of breast cancers (Alle, Henshall, Field, & Sutherland, 1998; 
Wang et al., 1994). The cyclin D2 gene is often methylated in breast cancer and 
overexpressing D2 in mouse mammary gland blocked alveolar differentiation with a low 
frequency of tumour formation (Evron et al., 2001; Kong et al., 2002; Sutherland & 
Musgrove, 2004). Cyclin D3 overexpressing mice developed normal mammary gland pre-
pregnancy but after repeated pregnancies, 73% of mice developed tumours (Pirkmaier et 
al., 2003). Expressing cyclin E1 during pregnancy and lactation resulted in papillary 
projections during pregnancy that disappeared during the resulting involution and after 8-
13 months only 10% of mice had developed tumours. Again, suggesting cyclin E1 as a 
weak oncogene in the breast, however it was shown to be abnormally expressed in ~40% 
of breast cancers with the protein being expressed as different isoforms ranging from 35-
50 kDa (Bortner & Rosenberg, 1997; Keyomarsi et al., 1994). Cell cycle regulation is a 




cells. The cell cycle is also an important part of treatment efficacy which often requires 
cells to be actively dividing for the drugs to be effective.        
Cell Metastasis 
Breast cancer remains a fatal disease for many women because of the ability of some cells 
to become metastatic, invade through the ECM, leave the primary tumour site, and 
establish a secondary tumour in vital organs such as the bones, brain, liver, and lungs. 
Invasion is a natural process that is needed for normal mammary gland development, 
however improper cell-ECM interactions can disrupt the homeostasis of the gland and lead 
to breast cancer and metastasis (Berrier & Yamada, 2007; Lock, Wehrle-Haller, & 
Stromblad, 2008).  
 Metastasis happens as a series of steps beginning with aberrant proliferation of cells 
to form a primary tumour. Cells that lose cell-cell adhesion properties, via E-cadherin and 
catenin misregulation (Chao, Shepard, & Wells, 2010), can disaggregate from the primary 
tumour site and invade through the basement membrane and ECM by way of MMPs and 
other proteases (Deryugina & Quigley, 2006).  
The integrins and growth factors have been described as the most important 
mediators of metastasis through their bi-directional signaling abilities (Ganguly, et al., 
2013). They are particularly important once a metastatic cell has reached the blood vessels 
and requires adhesion to blood cells to survive. In one study, constitutive αvβ3 activation 
was shown to increase breast cell metastasis in tail vein injections in mice, through 
adhesion and interaction with platelets (Felding-Habermann et al., 2001).  
β1-integrin was reported to be expressed in infiltrating ductal carcinoma cells and 




cancer (P. B. dos Santos, Zanetti, Ribeiro-Silva, & Beltrao, 2012; Jonjic, Lucin, Krstulja, 
Iternicka, & Mustac, 1993; Yao et al., 2007). Morini et al.(2000), were able to show that 
α3β1 was highly expressed in metastases as compared to the primary tumour site in patient 
samples and that α3β1 activity was necessary for MMP-9 protease activity and migration 
of MDA-MB-231 cells.  
β1-integrin can bind to many different α partners which can activate different 
downstream signaling pathways including a canonical pathway where integrins binding to 
their ligand and recruit FAK which autophosphorylates and associates with c-Src. This 
active FAK/Src complex can recruit and activate, through B-Raf, ERK and MAPK (Hou 
et al., 2016; Lambert, Ozturk, & Thiagalingam, 2012; Seguin, Desgrosellier, Weis, & 
Cheresh, 2015). The FAK/Src complex can also activate Ras which will, in turn, activate 
the Raf-MEK-ERK pathway. This β1-integrin/ERK pathway has been linked to metastasis, 
survival, and chemoresistance (Aoudjit & Vuori, 2001; Mierke, Frey, Fellner, Herrmann, 
& Fabry, 2011; Parvani, Galliher-Beckley, Schiemann, & Schiemann, 2013; Seguin, et al., 
2015). A summary of the β1-integrin/ERK signaling pathway is depicted in Figure 1.6 











Figure 1.6. β1-intergin signaling pathway in active and inactive conformation. 
Modified with permission: American Association for Cancer Research© (liscense # 









Inflammation and Breast Cancer 
The link between inflammation and cancer was proposed in 1863 by Rudolf Virchow who 
noted the presence of leukocytes in cancerous tissue (Coussens & Werb, 2002). It is known 
now that inflammation alone is not the cause of cancer, however it is thought to be 
favourable for cancerous cells to be in an environment with sustained and elevated 
inflammation (DeNardo & Coussens, 2007). There is a balance that has been observed 
where immune responses are critical for fighting cancer but chronic activation of these 
same immune cells contribute to cancer progression (DeNardo & Coussens, 2007). In 
breast cancer specifically, reduced overall survival of patients has been associated with 
systemic increases in inflammatory markers (Al Murri et al., 2006; Pierce et al., 2009). 
 During an acute inflammatory response, T helper 1 (Th1) CD4+ and CD8+ T cells 
can directly induce tumour cell death and will indirectly lead innate immune cells, such as 
macrophages, to attack tumour cells. Innate leukocytes are recruited by immunoglobulin 
factors secreted by B-cell lymphocytes to target the tumour cells (DeNardo & Coussens, 
2007). In contrast, during chronic inflammation Th2 CD4+ cells will supress the tumour 
cytotoxic activity of CD8+ cells. Innate cells are now polarized to protumour functions via 
cytokine secretion (IL-4, IL-13, IL-10, IL-6 and transforming growth factor beta (TGFβ) 
(DeNardo & Coussens, 2007). Innate tumour cells will accumulate in the tumour tissue and 
promote tumourigenesis and survival.  
 The immune response is not only implicated in anti or pro survival cues within the 
tumour but also contributes to tumour cell invasion (Radisky & Radisky, 2007). The 
urokinase-type plasminogen activator (uPA) receptor system, which can also activate the 




high levels of uPA is correlated with poor survival in breast cancer patients (Duffy, 2004; 
Mahmood, Mihalcioiu, & Rabbani, 2018; Meijer-van Gelder et al., 2004). Breast cancer 
cells are able to activate the surrounding immune and endothelial cells to produce uPA 
which ultimately leads to activation of the MMPs and increased degradation of the ECM 
to allow for cell invasion (Egeblad & Werb, 2002; Radisky & Radisky, 2007). 
Interestingly, proteases are required for cell invasion but not for cell migration because the 
cells can take on an amoeboid type of migratory behaviour (Friedl & Wolf, 2003; Wolf et 
al., 2003).  
 MMPs, in humans, are a family of 23 proteases that can regulate the tumour 
microenvironment through cleavage of almost all ECM components (Egeblad & Werb, 
2002). Activation of proMMPs requires the removal of the propeptide prodomain, which 
keeps the MMPs in the inactive form, through proteolysis, usually by other MMPs or serine 
proteinases (Egeblad & Werb, 2002; Nagase, Visse, & Murphy, 2006). MMPs are often 
highly expressed in metastatic cancer patients, as seen with MMP-2 and MMP-9 expression 
being highly upregulated in tumour samples from breast cancer patients and shown to 
increase invasion in breast cancer cells (Boire et al., 2005; Jones, Glynn, & Walker, 1999; 
Kondapaka, Fridman, & Reddy, 1997; Pellikainen et al., 2004; Stuelten et al., 2005). 
 Accurately recapitulating inflammatory and metastatic processes in a laboratory 
requires models beyond traditional two-dimensional in vitro cell culture techniques, which 
has led to the development of more accurate models to study the interactions between the 




Breast cancer treatment 
The above-mentioned properties and regulators of breast cancer will determine the 
treatment path that a doctor will follow. The current breast cancer treatment pathways as 
described by Cancer Care Ontario (2018) are divided at diagnosis between ductal 
carcinoma in situ, invasive breast cancer, distant metastases, and local/and or regional 
recurrence. Ductal carcinoma interventions are usually either breast conserving surgery or 
total mastectomy, followed by radiotherapy, and an optional endocrine therapy of 
tamoxifen for 5 years. For invasive carcinoma recommendation is for surgery and then 
based on surgical results, genetic and sub-typing factors patients are treated with endocrine 
therapy (tamoxifen), chemotherapy (ex. doxorubicin, cyclophosphamide, paclitaxel), 
and/or targeted therapy (Herceptin or pathway inhibitors). Sadly, for patients with distant 
metastases the recommended treatments include only palliative treatment, radiation and 
surgery, highlighting that metastatic breast cancer is considered incurable before treatments 
options are even tested for efficacy (2018). Recurrences are analyzed and categorized as 
being in one of the three other diagnostic groups and treated appropriately.  
 One common type of chemotherapy used in breast caner treatment are alkylating 
agents, such as cyclophosphamide, that substitute alkyl groups for hydrogen atoms on the 
DNA which inhibits protein synthesis and induces cell death (Brock & Hohorst, 1967; 
Kanekal, Fraiser, & Kehrer, 1992). Another type of drug is the taxanes, like paclitaxel, 
which stabilize microtubules to arrest the cell in G2 and prevent further cell division 
(Horwitz, 1992, 1994). The cytotoxic nature of chemotherapies, although necessary for 
cancer treatment, leaves patients with many temporary and permanent side effects. 




seriously heart and liver toxicity (Fraiser, Kanekal, & Kehrer, 1991; Hurd, 1973; 
McDonald et al., 2003; Subramaniam, Cader, Mohd, Yen, & Ghafor, 2013; van Boxtel et 
al., 2015).  
Dexamethasone (Dex) as an immunosuppressant  
To counteract the nausea, loss of appetite, and possible allergic reactions caused by 
chemotherapies, patients are given Dex as a standard practice. Dex is a synthetic GC that 
binds to the GC receptor in the cell cytoplasm and then transports to the nucleus to bind to 
the GC response elements of DNA to either induce or repress transcription of target genes 
(Chu et al., 2014). GCs regulate up to 100 genes in a cell and likely get their antiemetic 
properties from their ability to supress the immune response and serotonin receptors as well 
as other regulatory actions related to nausea (P. J. Barnes, 1998). Patients are usually 
administered Dex prior to and post treatment with the chemotherapeutics to prevent some 
of the side effects. The timing of Dex administration has been recently studied to determine 
toxicity of pretreatment with Dex but this particular study did not have a control “no Dex” 
group (Cook, McDonnell, Lake, & Nowak, 2016) and there are very few recent studies to 
report the severity of chemotherapy side effects with Dex administration compared to no 
Dex administration (Cook, et al., 2016). One older study was completed in 1974 with 
preterminal gastrointestinal cancer patients where the Dex administered group had an 
overall survival of 5.2 weeks and placebo group had an overall survival of 6.6 weeks. The 
patients that received Dex had improved strength and increased appetite so the study 
concluded the deceased survival time was worth the better quality at end of life (Moertel, 
Schutt, Reitemeier, & Hahn, 1974). This is the reality of most of the clinical studies that 




already terminal and may have decreased organ function, in the case of metastatic patients, 
so it is difficult to distinguish which side effects are caused by Dex and which are from the 
progression of the cancer (Cook, et al., 2016; Moertel, et al., 1974).  
 More concerning for breast cancer patients is the fact that there have been recent 
studies that show Dex and activation of the GC receptor mediate metastasis to distant sites 
in triple negative breast caner cells (Obradovic et al., 2019) and Dex increases cell survival 
in paclitaxel treated breast cancer cells (Crozier & Porter, 2015). The plethora of 
contradicting clinical reports that Dex suppresses cancer progression or promotes it 
highlights the need to dissect its role at the cellular level and determine its regulation on 
specific cellular processes by using translational research models that can then be applied 
to a clinical setting.  
The use of natural health products (NHPs) as immune modulators and antioxidants 
Because of the detrimental side effects seen from long term use of many synthetic 
glucocorticoids, like Dex, and even non-steroidal anti-inflammatory drugs, such as 
ibuprofen and aspirin, there has been a movement towards using naturally derived products 
or NHPs. Health Canada defines NHPs as “vitamins and minerals, herbal remedies, 
homeopathic medicines, traditional medicines, probiotics, and other products like amino 
acids and essential fatty acids” and must be safe to be sold without a prescription (Natural 
Health Products, 2018). Studies of different anti-inflammatories have shown some positive 
effects against breast cancer cells. Interestingly, Cardomonin, a chalcone (aromatic ketone) 
isolated from Alpiniae katsumadai, is a known anti-inflammatory agent and was able to 
induce apoptosis in MDA-MB-231 breast cancer cells through inhibition of Hypoxia-




phosphorylation and induced reactive oxygen species (ROS) accumulation (J. Jin et al., 
2019). ROS is usually seen as detrimental for people as it benefits metabolism of breast 
cancer cells but over-accumulation in the cell leads to excessive damage and apoptosis 
(Starkov, 2008). Although excessive ROS in cancer cells can lead to cancer cell death, 
antioxidants that remove ROS are being reported as effective for use as cancer preventives 
with the intention that preventing ROS accumulation with add a protectant from cancer 
development (C. Y. Chen, Kao, & Liu, 2018; Chikara et al., 2018; Goodman, Bostick, 
Kucuk, & Jones, 2011; Lin, Gong, Song, & Cui, 2017; Padayatty et al., 2003).    
 Antioxidants are also being studied for use as chemotherapy co-medication. 
Production of ROS are implicated as the cause of adverse side effects of chemotherapies, 
especially alkylating agents, because of the free radicals released when the drug interacts 
with DNA (Joensuu, 2008). Chemotherapies are systemic drugs and as such ROS can 
accumulate in the heart, liver, and other vital organs to cause serious toxicity in cells 
outside of the tumour area (Singh, Bhori, Kasu, Bhat, & Marar, 2018).  Antioxidants may 
be able to remove the ROS accumulation in these vital organs and help prevent toxicity of 
chemotherapeutics although this needs to be studied further to determine if antioxidants 
are beneficial or detrimental to cancer patients (El-Sheikh, Morsy, & Okasha, 2017; Ozben, 
2014, 2015).       
Modeling Mammary Development and Tumourigenesis in 3D Cell Culture  
Normal human mammary development has primarily been studied on tissue obtained from 
necropsies or from patients undergoing some form of mammoplasty (Anbazhagan, et al., 
1991; Jolicoeur, et al., 2003; Monaghan, et al., 1990; Tobon & Salazar, 1974). Human 




already in a malignant state so the very first stages of early tumour progression are difficult 
to study in humans which has led to other models being developed to study which genes 
and hormones are essential for proper gland development and how this may link to the 
initiation and/or progression of breast cancer. Although mouse mammary glands develop 
differently than human glands, the alveolar structures are almost identical which provides 
an excellent model of alveolar development and cancer initiation (Anbazhagan, et al., 1991; 
Cardiff & Wellings, 1999; Javed & Lteif, 2013). While they provide a wealth of scientific 
information, mouse studies are very expensive and time consuming. It has become 
necessary to develop models that will provide a biologically relevant environment to study 
cell behaviour but also one that is cheaper and faster than conventional in vivo mouse 
models. 3D in vitro cell culture and zebrafish xenotransplants are two model systems that 
were developed to address the disadvantages of mouse models.  
 Conventional in vitro cell culture systems consist of growing cells on two-
dimensional (2D), plastic culture plates which allow the cells to proliferate but deprives 
them of many of the environmental cues that would be present in an in vivo system. 
Culturing the cells in the presence of a relevant ECM is an important step in the study of 
mammary gland morphogenesis and breast cancer initiation. An ECM mixture was isolated 
from Engelbreth-Holm-Swarm mouse sarcoma cells that contained known components of 
the basement membrane and was biologically active, allowing cells to form polarized 
structures similar to those found in vivo (Kleinman & Martin, 2005; Qu et al., 2015). This 
ECM, marketed as Matrigel or Cultrex® basement membrane extract (BME) (containing 
primarily Laminin I and type IV Collagen), can be used with many different cell systems 




cells. One of the most common cell lines used in 3D in vitro human mammary studies are 
MCF10A cells and their derivatives (Qu, et al., 2015). Long term culture of normal, 
untransformed mammary epithelial cells is difficult and so the isolation of immortalized 
MCF10A cells makes them an asset to mammary gland research. MCF10A cells were 
derived from cells which were originally isolated from a female undergoing a mastectomy 
to remove fibrocystic tissue but who had no signs of abnormal or diseased tissue (Soule et 
al., 1990). These cells were spontaneously immortalized in culture, allowing for a cell line 
for long-term studies, and show a loss of the chromosome locus containing the p16 and 
p14ARF genes. They are also lacking ER expression but have wild-type p53 (Debnath, 
Muthuswamy, & Brugge, 2003; Qu, et al., 2015; Soule, et al., 1990). Importantly, the 
MCF10A cells are able to form polarized acini with hollow lumens when cultured in 
basement membrane extract that resemble alveolar structures found in human breast tissue 
(Debnath, et al., 2003; Soule, et al., 1990). The one major caveat of using MCF10As is that 
they do not always form the same tight junctions that are found in the human breast. For 
example, MCF10A cells do not express the apical polarity protein, zonula occludens,  
which should accumulate on the apical side of the cells, against the lumen (Plachot et al., 
2009).  
 MCF10A acini formation has been extensively described (Debnath, et al., 2003; 
Soule, et al., 1990; Underwood et al., 2006) and follows the same developmental steps in 
normal culture conditions. This makes it a great model for gene manipulation because any 
developmental changes to the acini can be easily recognized. They will also develop a 
lumen that is larger in size than that found in vivo but will maintain its size from day 12 to 




cells undergoing cell death in the single layer of cells that form the lumen (Underwood, et 
al., 2006). 
Untransformed MCF10A cells do not engraft into immunodeficient mice, however 
when Dawson et. al (1996) transformed them with c-Ha-ras, the cells were able to form 
nodules that persisted long-term, formed hyperplasia, and sporadically become 
tumorigenic. These engraftments were collected from the mice and cultured to create the 
MCF10AT1 (AT1) cell line (Dawson, Wolman, Tait, Heppner, & Miller, 1996). Serial 
xenografts and isolation of resulting tumours led to the development of the malignant 
MCF10CA1 and MCF10DCIS lines (Santner et al., 2001). These cell lines present an 
advantageous in vitro tool to study breast cancer progression as they phenotypically 
represent early to late stage breast cancer when cultured in 3D ECM assays.        
 Although this model has the above advantages over 2D cell culture techniques, it 
still does not incorporate all of the elements of the immune system that are important 
regulators of mammary morphogenesis and metastasis. Using an in vivo model that has an 
intact immune system is a more accurate way to study breast cancer metastasis and 
treatment efficacy.       
Using Zebrafish to Model Human Cancers in vivo  
Zebrafish models have many advantages over in vitro models because of their distinct, well 
characterized development, high fecundity, and intact innate but delayed adaptive immune 
systems. Together these attributes provide a low-cost, high efficiency model for human 




Zebrafish morphological development 
Zebrafish embryos will develop asynchronously, even eggs from the same clonal strain, 
same clutch and raised in the same uncrowded conditions (Streisinger, Walker, Dower, 
Knauber, & Singer, 1981; Westerfield, 1993). For this reason, staging embryos based on 
morphology is more accurate than strictly based on time post fertilization without 
microscopic examination of morphology. Early embryo development can be divided into 
stages or periods described in depth by Kimmel et al. (Kimmel, Ballard, Kimmel, Ullmann, 
& Schilling, 1995). Development begins with the zygote period, which lasts approximately 
45 minutes (mins) from time of fertilization until the first cell cycle. The next stage is the 
cleavage period which includes cell cycles 2-7 and this period lasts only about 1 hour (hr) 
and 45 mins. The blastula period lasts from hr 2 1/4 to hr 4 2/3 and first has rapid cell 
cycles (8-9) followed by longer asynchronous cycles. The epiboly (the spreading of the 
blastoderm over the yolk cell) appears in the dome stage of this period. The gastrula period 
lasts longer (hrs 5 ¼-10) and involves gastrulation and convergence of the cells into the 
embryonic shield, ending with the appearance of the tail bud. The segmentation period (hrs 
10 1/3-22) contains the development of the somites which are paired mesodermal segments 
that are the precursors for muscle, cartilage, and bone and will remain apparent until 
adulthood (Stickney, Barresi, & Devoto, 2000). Primary organogenesis, early movements, 
and the tail are visible during this period. The pharyngula period, from hrs 24-42, contains 
the stages where the body straightens away from the yolk sac, the fins develop, and 
circulation and pigmentation begin. The final period is the hatching period, from hrs 48-
72, and this is when cartilage develops in the head and pectoral fin, hatching occurs, and 




food-seeking behaviour. The stages are described by hr below in Table 1.2 and depicted 






























The newly fertilized egg through the completion of the first 
1-cell 0 zygotic cell cycle 
Cleavage period 
 
Cell cycles 2 through 7 occur rapidly and synchronously 
2-cell .75   
4-cell 1   
8-cell 1.25   
16-cell 1.5   
32-cell 1.75   
64-cell 2   
Blastula Period 
 
Rapid, metasynchronous cell cycles (8,9) give way to  
128-cell 2.25 lenghtened, asynchronous ones at the midblastula  
256-cell 2.5 transition; epiboly then begins 
512-cell 2.75   
1k-cell 3   
High 3.33   
Oblong 3.67   
Sphere 4   
Dome 4.33   
30%-epiboly 4.67   
Gastrula period 
 
Morphogenetic movements of involution, convergence, 
50%-epiboly 5.25 and extension form the epiblast, hypoblast, and embryonic  
germ-ring 2.67 axis; through the end of the epiboly 




75%-epiboly 8   
90%-epiboly 9   
Bud 10   
Segmentation Period 
 
Somites, pharyngeal arch primordia, and neuromeres  
1-somite 10.33 develop; primary organogenesis; earliest movements; the  
5-somite 11.67 tail appears 
14-somite 16   
20-somite 19   
26-somite 22   
Pharyngula period 
 
Phylotypic-stage embryo; body axis straightens from its early 
Prim-5 24 curvature about the yolk sac; circulation, pigmentation, and  
Prim-15 30 fins begin development 
Prim-25 36   
High-pec 42   
Hatching period 
 
Completion of rapid morphogenesis of primary organ  
Long-pec 48 systems; cartilage development in head and pectoral fin;  
Pec-fin 60 hatching occurs asynchronously 
Protruding-mouth 72 Early larva; swim bladder inflates; food-seeking and active  
    avoidance behaviours 
 
Table 1.2. Early stages of Zebrafish development.  
Summary of the early developmental stages of the zebrafish beginning with fertilization 
and ending with the early larval stage. Table was modified from stages described by 









Figure 1.7. Staging series for key developmental timepoints in early zebrafish 
development. 





Zebrafish immune system development and maturation  
One of the advantages of using zebrafish embryos over mammals, in modeling human 
cancer in vivo, is the delay in development of an adaptive immune system that allows for 
xenotransplantation and engraftment of human cells without the need for immune 
compromised embryos. It has been shown that adult zebrafish possess all blood cell 
lineages that mammals do, however the adaptive immune system is not fully mature until 
approximately 4 weeks post fertilization (Lam, Chua, Gong, Lam, & Sin, 2004; Meijer & 
Spaink, 2011; Trede, Langenau, Traver, Look, & Zon, 2004).  
Innate immune system 
The innate immune system develops almost immediately in the zebrafish embryos with 
hematopoiesis being initiated during the first day of embryo development when the 
hemangioblasts differentiate into myeloid cells and erythroid cells are formed (Bertrand & 
Traver, 2009; Lam, et al., 2004). This primitive immune system is set up to protect the 
embryo from infection and ensure survival of the embryo.  
 The first line of defense for the embryos are the pattern recognition receptors that 
are cell-surface receptors that will recognize invading pathogens and initiate the immune 
response (van der Vaart, Spaink, & Meijer, 2012). The most well-known class of pattern 
recognition receptors are the 10 proteins in the Toll-like receptor (Tlr) family. Zebrafish 
have many orthologs of mammalian TLRs and some fish specific Tlrs (Jault, Pichon, & 
Chluba, 2004; Meijer et al., 2004) that will recognize lipopeptides, double-stranded RNA, 
and flagellin, amongst other foreign particles (van der Vaart, et al., 2012). Activation of 
the Tlrs will lead to activation of transcription factors in the Nfκb and Stat families, 




Nucleotide-binding-oligomerization-domain like receptors will recognize 
pathogens, that have escaped the Tlrs and have made it to the cytosol, and then activate 
Nfκb, Mapk, and caspase-1 pathways which will lead to the production of pro-
inflammatory cytokines such as the interleukins (Il-1β, Il-2, Il -4, Il -6, Il -8, Tnfα, etc.). Il-
10 is an anti-inflammatory cytokine but can also be secreted in response to 
lipopolysaccharides (G. Chen, Shaw, Kim, & Nunez, 2009; Secombes, Wang, & Bird, 
2011; Shiau, Monk, Joo, & Talbot, 2013). As in humans, the immune response is crucial 
for proper development, for example Il-3 is needed to promote survival and proliferation 
of hematopoietic stem cells (Robin et al., 2006).  
Adaptive immune system 
The thymus, T cells, and B cells, as well as other components of the adaptive immune 
system are conserved between mammals and zebrafish making it an appropriate model for 
immune studies (Trede, et al., 2004). The thymus begins developing around 48 hrs post 
fertilization (hpf), although there is no interaction between the thymus epithelium and T 
cells until around 3 weeks later (Lam, et al., 2004). T cell precursors are present in the 
thymus beginning at about 72hpf as seen by rag-1 expression however in situ hybridization 
was unable to detect T cells outside of the thymus during the first 3 weeks of development 
(Langenau et al., 2004). It is not until 4-6 weeks post fertilization that zebrafish begin 
producing antigens as demonstrated by Lam et al. who immunized zebrafish with bacteria 
to determine the timing of antigen production (Lam, et al., 2004). 
Using zebrafish to model human cancer 
This late onset of adaptive immunity function allows for zebrafish to be used in human 




before maturation of the adaptive immune system. This property was first exploited by Lee 
et al. in 2005 who injected primary human melanocytes and malignant melanoma cells into 
a 3.5-4.5hpf embryo and determined that the microenvironment of the fish could influence 
the human cells (L. M. Lee, Seftor, Bonde, Cornell, & Hendrix, 2005). The normal 
melanocytes were found in the skin of all of the transplanted embryos where as the 
malignant cells were dispersed throughout the embryos because of their dedifferentiated 
state (L. M. Lee, et al., 2005). Since then, numerous labs have studied cancer processes in 
the zebrafish xenograft model. Cell metastasis can be quantified by injecting cells into the 
yolk sac of the embryo and since it is an enclosed organ, cells have to actively invade 
through the syncytial layer to get to the body of the embryo (Kimmel & Law, 1985). Some 
examples of xenografts using breast cancer cells have shown that cells isolated from 
mammosphere stem cell assays will invade and migrate at rates high than cells from 
monolayer cultures (Eguiara et al., 2011) and that depletion of αv-integrin in breast caner 
cells impaired metastasis of implanted cells (Li et al., 2015).  
Another important set of assays that have been developed in zebrafish are those 
pertaining to cancer drug toxicity, efficacy, and discovery. Zebrafish provide a high 
throughput platform to test many compounds, at many different concentrations, very 
quickly (He et al., 2013; McGrath & Li, 2008; Veinotte, Dellaire, & Berman, 2014). Their 
transparency until later in the larval stage (2+ weeks) make monitoring organ development 
and toxicity in live embryos possible. Combining drug treatment with xenografts allows 
for monitoring of drug efficacy in vivo (Pruvot et al., 2011). Also, because zebrafish have 
orthologs of 71% of human proteins and 82% of disease-causing humans proteins, they 




exposed to similar metastatic influences, such as Mmps and cytokines that are present in 
mammals (Howe et al., 2013; Letrado, de Miguel, Lamberto, Diez-Martinez, & Oyarzabal, 
2018). 
Zebrafish are emerging as an attractive model to study human cancer in vivo 
because of its intact immune system and a microenvironment that is similar to human, it is 
much cheaper than mouse models and it is more high throughput due to large egg clutch 



















Hypothesis and objectives  
This work will use a zebrafish translational model optimized in our lab to investigate the 
effects of anti-inflammatories, both synthetic and natural, on breast cancer cells and 
investigate their efficacy in vivo. Secondly, this work will investigate the role of Spy1 in 
mammary morphogenesis and metastasis.  
 We hypothesize that Dex contributes to breast cancer cell metastasis and enhanced 
toxicity of chemotherapeutics and that NHPs offer alternative methods to prevent 
inflammation in vivo. We also hypothesize that Spy1 expression is tightly regulated during 
normal mammary gland morphogenesis and altered expression of Spy1 will play a pivotal 
role in breast cancer metastasis processes.    
These hypotheses will be addressed through the following objectives: 
• Determine the effects of Dex treatment on breast cancer metastasis in vitro and in vivo  
• Determine the toxicity of Dex treatment in combination with chemotherapeutics in a 
zebrafish model 
• Standardize a translational zebrafish model to study human cancer in vivo for use in 
industry and evaluate the efficacy of NHPs as anti-inflammatories and antioxidants 
using this model 
• Elucidate the role of Spy1 in normal mammary morphogenesis and breast cancer 
metastasis 
The zebrafish model proposed in this work will provide the tools needed to perform 
high throughput drug assays in academic and industrial research settings. Most importantly, 
data obtained from this research will provide a better understanding of inflammatory 




progresses to become metastatic. Ultimately, we hope to provide some insight into breast 
cancer processes and improve the treatment options for metastatic breast cancer so it will 
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Breast cancer is a heterogeneous disease that can be classified into subtypes based on gene 
expression profiles or histological presentation of levels/presence of hormone or growth 
factor receptors, e.g., estrogen receptor (ER), progesterone receptor (PR), and human 
epidermal growth factor receptor 2 (HER2)/neu (Reis-Filho & Tutt, 2008; Weigelt, 
Baehner, & Reis-Filho, 2010). These receptors serve as molecular targets for many 
conventional anti-cancer therapies, e.g., tamoxifen and trastuzumab (Herceptin). ER-
positive and PR-positive cancers generally fall under the luminal genomic subtype, while 
those lacking ER, PR and HER2 amplification, called triple negative breast cancer 
(TNBC), tend to fall under the basal or claudin-low genomic subtypes. Approximately 15% 
of breast cancers are triple negative. Statistically this group represents a younger population 
and the disease is among the most aggressive, in part due to the lack of directed therapies 
(Abramson, Lehmann, Ballinger, & Pietenpol, 2015). Most breast cancer related deaths are 
due to metastatic spread of the disease and not the primary tumour itself (Weigelt, Peterse, 
& van 't Veer, 2005). For metastasis to occur, several important cellular characteristics are 
needed and include the ability to: survive (elude apoptosis) and grow/proliferate at the 
primary tumour site; invade through boundaries at the primary site; move or migrate, 
whether in circulation or within neighboring tissues; extravasate into a secondary site; and 
finally, survive and colonize the secondary site (Zhang, Ma, & Fan, 2010). TNBC and 
metastatic ER-positive or PR-positive disease relies heavily on standard of care 
chemotherapy and do not have protocols specifically targeting metastatic cancer 




Chemotherapy has saved countless cancer patients’ lives over the past twenty years 
(Printz, 2011). Unfortunately, these treatments, and in many cases the vehicle in which 
they are dissolved, cause unwanted side effects. To lessen and even prevent many of these 
side effects, glucocorticoids (GCs), e.g., dexamethasone (Dex), are administered in 
advance of chemotherapy (Kloover, den Bakker, Gelderblom, & van Meerbeeck, 2004). 
Dex mediates anti-emetic effects through the GC receptor (GR). Active GR can regulate 
gene expression of approximately 10% of the human genome (Buckingham, 2006). Active 
GR is involved in development and regulation of a plethora of physiological processes 
including, but not limited to: inflammation, blood pressure, sensitivity to catecholamines, 
neuronal and glial cell activity, brain, breast, and bone development, homeostasis of body 
temperature, as well as carbohydrate, protein, and lipid metabolism (Buckingham, 2006). 
Moreover, GCs can affect cellular process of division, survival, apoptosis, migration and 
invasion which are critical processes also implicated in metastasis of cancer (Hayashido, 
Shirasuna, Sugiura, Nakashima, & Matsuya, 1996; Zheng, Izumi, Li, Ishiguro, & 
Miyamoto, 2012).  
Given the heavy dependency on Dex during chemotherapy treatment, and the vast 
cellular processes affected by this potent steroid, we and others have examined the effects 
of Dex on breast cancer cell biology. The literature has established that Dex has 
demonstrated effects on overriding cell death processes initiated by chemotherapy drugs in 
several solid cancers including breast cancer (Crozier & Porter, 2015; Mikosz, Brickley, 
Sharkey, Moran, & Conzen, 2001; Runnebaum & Bruning, 2005). Recently, Obradović et 
al. determined that glucocorticoids were able to promote breast cancer metastasis in mouse 




2019).   However, they did not distinguish between triple negative and ER+ patient 
transplants, nor did they transplant ER+ cell lines into the mice.  Despite these advances, 
whether different subtypes of breast cancer are differentially affected by Dex has not been 
investigated.  
In this work we demonstrate that that GR levels correlated to breast cancer subtypes 
with highest expression found in the TNBCs and relatively low expression found in luminal 
breast cancer cell lines. Treatment of breast cancer cells with Dex increased overall cell 
numbers, invasiveness, and migratory capacity, compared to non-treated cells, and TNBCs 
demonstrated the most pronounced phenotypes in response to Dex. This work, while still 
far from providing any clinical conclusions, has profound implications for breast cancer 















Materials and methods  
Cell culture  
Human breast cancer cells MCF7 (HTB22; ATCC); MDA-MB-231 (HTB26; ATCC), 
Hs578t (HTB126; ATCC), and MDA-MB-468 (HTB132; ATCC) cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma). T47D cells (HTB-133; ATCC) 
were cultured in RPMI-1640 Medium (Sigma) with 2 units/ml of insulin (Sigma). SK-BR-
3 cells (HTB-30; ATCC) were cultured in McCoy’s 5A Medium (ATCC). All cells were 
supplemented with 10% fetal bovine serum (FBS; Sigma) and 1% Penicillin and 
Streptomycin and were maintained in an atmosphere of 5% CO2 at 37˚C. For passaging, 
seeding, and quantification of cell numbers, cells were collected with 0.25% trypsin and 
counted using the TC10™ Automated Cell Counter (BioRad). 
Compounds and antibodies 
The following antibodies were used at a dilution of 1:1000: actin (MAB1501R; Chemicon) 
and GR-α (3626-1; Epitomics). Secondary antibodies used were horse radish peroxidase 
(HRP)-conjugated anti-mouse IgG (A9917; Sigma) and anti-rabbit IgG (A0545: Sigma). 
Charcoal (C6241; Sigma), paclitaxel (T7402; Sigma), Dex (DN1187; BioBasic), and RU-
486 (Mifepristone; M8056; Sigma). 
Immunoblotting 
Samples were lysed with 0.1% NP40 buffer supplemented with Leupeptin (10ug/ml; 
BioBasic), Aprotinin (10μg/ml; Sigma), and phenylmethylsulfonyl fluoride (PMSF) 
(1mM; BioBasic). Samples were analyzed by 10% sodium dodecyl sulphate-




difluoride (PVDF) membrane. Primary antibodies were applied and incubated over-night 
at 4°C at dilutions specified above. Proteins were detected via treatment with Perkin-Elmer 
Enhanced Chemiluminscence reagent/ enhanced chemiluminescence (ECL) Western Gel 
Substrate (Perkin Elmer) and quantified using FlourChem HD2 software (AlphaInnotech; 
Perkin Elmer). 
Apoptotic assays 
Caspase 3/7-glo assay (Promega) was used to measure the apoptotic state of treated cells. 
24hrs post-treatment cells were collected via trypsinization and lysed. 50µl of Caspase-
Glo® 3/7 reagent was added in each well of a white-walled 96-well plate containing 50µl 
of lysis buffer as blank, negative control cell lysates, or treated cell lysates with the final 
concentration of 1µg/µl. Contents were gently mixed in the wells using a plate shaker at 
300-500rpm for 30sec. Cell lysates were incubated at room temperature for 30min and the 
luminescence of each sample was measured using Wallac Victor 1420 plate reader. 
Migration assay 
Cells were seeded (1 x 105) in 500μL of serum-free media in Falcon Cell Culture Inserts 
(Becton-dickinson) in the wells of a 12-well cell culture plate with 1ml of complete media 
(serum-free control). Cells were treated with either ethanol (vehicle control) or different 
concentrations of Dex and incubated for 24hrs. Following treatment, the inserts were 
carefully removed, cells that did not migrate through the pores and therefore remained on 
the upper side of the filter membrane were gently separated, and the migrated cells were 
quickly stained with 400μL of 1% Crystal Violet in 2% ethanol for 10min. The inserts were 
then submerged in water to remove excess Crystal Violet and air-died. Different views of 




microscope. The crystal violet was then released with extraction buffer, containing 10% 
acetic acid, and the absorption of the samples was measured at 590nm using a Wallac 
Victor 1420 plate reader. 
Invasion assay 
Prior to seeding, cell culture inserts were coated with 100µl of Cultrex® Reduced Growth 
Factor Basement Membrane Extract (Trevigen), diluted to 5mg/ml, for 4hrs at 37°C to gel. 
Cells were then seeded (1 x 105) in 500μL of serum-free media in inserts in the wells of a 
6-well cell culture plate with 1ml of complete media (serum-free control). Cells were 
treated with ethanol (vehicle control) or different concentrations of Dex and incubated for 
24hrs. Following treatment, the inserts were carefully taken out, cells that did not migrate 
through the pores and therefore remained on the upper side of the filter membrane were 
gently removed, and the migrated cells were quickly stained with 400μL of 1% Crystal 
Violet in 2% ethanol for 10min. The inserts were then submerged in water to remove excess 
Crystal Violet and air-died. Different views of the cells attached to the membrane were 
imaged using a Leica inverted fluorescence microscope. The crystal violet was then 
released with extraction buffer, containing 10% acetic acid, and the absorption of the 
samples was measured at 590nm using a Wallac Victor 1420 plate reader. 
Animal care and handling 
Wild-type Zebrafish (Danio rerio) were handled in compliance with local animal care 
regulations and standard protocols of Canada. Adult fish were kept at 28.5°C and bred 




Implantation procedure, treatment, and imaging 
Zebrafish eggs were collected after fertilization and kept in E3 embryo media (5mM NaCl, 
0.17mM KCl, 0.33mM CaCl2, 0.33mM MgSO4, 10
-5% Methylene Blue) at 28.5°C in an 
incubator until ready to inject. Before injection 500,000 MDA-MB-231 cells in 500µl of 
serum-free media were labeled with 10µL of DiI (red) (Vybrant; Invitrogen) at 37°C for 
20min. MCF7 cells were labelled with the same procedure using DiO (green) (Vybrant; 
Invitrogen). Cells were washed with 1ml of serum free media twice and resuspended in 
50µl of serum free media, kept at 37°C for 20min, and placed on ice until ready to inject. 
Before injection both labelled cell lines were mixed at equal proportions in an Eppendorf 
tube. 48hrs post-fertilization (hpf) the embryos were dechorionated with fine tip forceps 
and anesthetised with 0.168 mg/ml of Tricaine (Sigma). 50-100 of each labeled cell 
line/9.2nl were loaded into glass capillary needles and injected into the yolk sac of each 
embryo using a Nanoject II (Fisher Scientific). After injection, embryos were placed in E3 
embryo media and 1hr post-implantation (hpi) were examined using a Leica fluorescence 
stereomicroscope to exclude any embryo with cells outside of the implantation area. 
Following injection, zebrafish were transferred to 96-well plates, with one zebrafish per 
well. Dex was diluted to a final concentration of either 10µM or 100µM in E3 embryo 
media and added to each well of the treatment fish. DMSO was added to the control fish. 
24hpi and 24 hrs post treatment (hpt) the fish were anesthetized with 0.168 mg/ml Tricaine 
in a 96-well plate, with one embryo per well.  The embryos were imaged using a Leica 
fluorescence microscope. This was repeated at 48hpi and 96hpi with fresh Dex being added 




 All image analysis was completed using ImageJ software and was adapted from a 
previously described method for animal bio-imaging assays (Ghotra et al., 2012). The 
image for each embryo was imported into ImageJ, aligned to the same orientation, and 
cropped to the same size. The images were converted to a 32-bit gray-scale and the 
threshold was adjusted to eliminate background pixels. The injection sites were chosen as 
the midpoint of the yolk sacs. Using the measure function, the exact coordinates for the 
injection site were measured. The Analyze Particle tool was then used to record the 
coordinates of each labeled cell focus within the entire embryo. The coordinates of each 
tumour focus were corrected to the injection site coordinates using the formula: (Xfoci-
Xorigin,Yfoci-Yorigin). For each corrected focus coordinate the distance travelled from the 
injection site was calculated using the formula: √(Xcorrected
2+Ycorrected
2). The cumulative 
distance (CD) of all foci was calculated per embryo and averaged within an experimental 
group to determine mean CD. Each embryo was scored as having either cells metastasized 
to the tail or no metastasis and the percentage of fish with metastases was calculated.   
qRT-PCR Analysis 
MCF7 and MDA-MB-231 cells were collected after Dex treatment and RNA extracted 
using RNeasy Plus Mini Kit (Qiagen; 74134).  Reverse Transcription of 1ug of RNA was 
performed using the established QuantaBio qScript cDNA Supermix protocol. Relative 
RNA expression was measured using GAPDH as an endogenous control. The following 
sequences were used: MMP9(Li, Qiu, Li, & Wang, 2017) 5′-
ACGCACGACGTCTTCCAGTA-3′ and 5′-CCACCTGGTTCAACTCACTCC-3′; 
TGFβ1(Chen et al., 2015) 5′-TCGCCAGAGTGGTTATCTT-3′ and 5′-




TAAGCCCAGGAGTTGCTTTG- -3′ and 5′- GCAGAGAGGCTGTGCTCCTA-3′; 
IL1B(Nickel et al., 2018)5′- CATGGCCACAACAACTGACG-3′ and 5′- 
AGCCATGGCAGAAGTACCTG -3′; IL6(Zhao et al., 2014) 5′- 
GAGATGCCGTCGAGGATGTA-3′ and 5′- CTTCGGTCCAGTTGCCTTCTC -3′ 
Statistical analysis 
Student t test was employed using Statistica software. For percent metastasis the two-
proportion Z test was performed.  All other results are expressed as mean ± SEM or mean 
















TNBCs express higher levels of GR-α 
Dex mediates its effects through the GR; hence, we assessed the relative levels of GR-α 
across a panel of breast cancer cell lines. Three TNBC (MDA-MB-231, Hs578t, MDA-
MB-468), and three luminal subtype (MCF7, SK-BR-3, T47D) cell lines were used (Figure 
2.1). The highest levels of GR protein were expressed in TNBC cells line with the highly 
aggressive MDA-MB-231 cells displaying the highest levels, followed by the Hs578t cells 
and the MDA-MB-468 cells, respectively. Expression was significantly reduced in the 





Figure 2.1. Relative expression of GR-α in triple negative and luminal breast cancer cell 
lines. 
TNBC cell lines MDA-MB-231, Hs578t, and MDA-MB-468 and luminal breast cancer 
cell lines MCF7, SK-BR-3 and T47D were lysed and subjected to Western blotting. 
Endogenous GR-α levels were measured by immune-blotting. Densitometry analysis of 
three separate experiments, indicating GR-α protein levels normalized to actin, (lower 







Dex increases cell numbers of breast cancer cells in vitro.  
To assess whether Dex affects the survival and growth of breast cancer cells of differing 
subtype, we treated cells representing both TNBC (MDA-MB-231, Hs578t), and luminal 
subtypes (MCF7, SK-BR-3, and T47D) with vehicle (control) or Dex (1μM) for 24 hrs to 
mimic clinical protocol (Figure 2.2). The two TNBC cell lines, MDA-MB-231 and Hs578t, 
showed the greatest increase in total cell number at 38% and 24% compared to non-treated 
cells (Figure 2.2 A & C). The highest cell number amongst the luminal breast cancer cell 
lines correlated with GR-α expression in the MCF7s with 22% higher count in Dex-treated 
compared to non-treated cells (Figure 2.2 B & C). The MCF7s have the highest GR-α 
expression amongst the luminal cell lines (Figure 2.1). The SK-BR-3 and T47D cell lines 
displayed the smallest difference in cell number between treated and non-treated at 8% and 
7% difference, respectively (Figure 2.2 B & C). Hence, Dex-mediated effects on total cell 
numbers correlate with the protein levels of GR-α (Figure 2.1). 
To assess whether the increase in cell number was due to proliferative activity or 
anti-apoptotic activity, we analyzed caspase 3 and 7 activity under the same conditions 
using the TNBC cell lines (MDA-MB-468 and Hs578t) and the luminal (SK-BR-3 and 
T47D) cell lines (Figure 2.2 D-E). All four cell lines showed decreases in caspase 3 and 7 
activity indicating that the Dex-mediated difference in cell number between Dex-treated 
and non-treated cells may be a result of a Dex-induced pro-survival, and not necessarily 
increases in proliferation. The cell lines expressing the highest levels of GR-α also 
demonstrated greater sensitivity to Dex-mediated inhibition of the caspases. The Hs578t 
cells showed 60.7% decrease in caspase 3 and 7 activity. The luminal cell lines SK-BR-3 





Figure 2.2. Impact of Dex on total cell number 24hrs post-treatment. 
(A) TNBC cell lines MDA-MB-231 and Hs578t and (B) luminal breast cancer cell lines 
MCF7, SK-BR-3 and T47D were treated with vehicle (control) or Dex for 24hrs. Cells 
were collected and counted for total cell number. (C) Graphic representation of the fold-




cell line Hs578t and (E) luminal breast cancer cell lines SK-BR-3, and T47D were treated 
for 24hrs with vehicle (control) or Dex for 24hrs. Cells were collected and lysed. Luciferase 
activities of the lysates were measured using equal amounts of cell lysate mixed with 
Caspase 3/7 Glo buffer and luminescence was quantified by spectrophotometry. Graphs 
show the mean value of at least three experiments, each performed in triplicate, upon which 





















Dex increases migration of TNBC cell lines in vitro. 
The migratory properties of a cell are key parameters in determining metastatic capacity. 
To assess whether Dex could alter the migration of breast cancer cell lines in vitro, we 
performed cyto-select transwell assays. TNBC cells, MDA-MB-231, were treated with 
vehicle (control) or a dose range of Dex and cell migration was measured by microscopy 
(Figure 2.3; upper panels) and quantified by spectrophotometry (Figure 2.3 A, lower 
panel). A statistically significant increase in migration was observed compared to control 
cells in the MDA-MB-231 cell line. We repeated the migration assay for the TNBC cell 
line MDA-MB-468 with vehicle (control) and with Dex (1μM). We observed a statistically 
significant increase in migration (Figure 2.3 B). The luminal breast cancer cell line T47D 
did not display an increase in migration following Dex treatment (Figure 2.3 E).  
To ensure that increases in cell number were not due to Dex-induced proliferation 
or enhanced survival in the serum-free conditions, MDA-MB-231 and MDA-MB-468 cells 
were seeded in serum free media on tissue culture plates and grown with vehicle (control) 
or Dex (1μM) for 24hrs (the length of the entire migration assay). There was no change in 
cell number between treated and non-treated cells in these media conditions (Figure 2.3 C-
D). Thus, it is unlikely that proliferation effects can account for the migration phenotype. 
To ensure that the same would hold true for cells that were in complete media for the 
duration of the assay (i.e., putative cells that migrated immediately after seeding), MDA-
MB-231 and MDA-MB-468 cells were grown with vehicle (control) or Dex in serum-free 
media and then the media was replaced with complete media for an additional 24hrs. No 
significant change in cell number was observed (Figure 2.3 C-D). Thus, it is unlikely that 




cells once in complete media (as both would be in complete media) during the assay 
timeframe. It is notable that when MDA-MB-231 cells were left for an additional 24hrs 
(total time in complete media = 48hrs), a statistically significant difference in cell number 
was observed for Dex-treated cells suggesting a Dex-mediated proliferative or pro-survival 























Figure 2.3. Impact of Dex on migration of triple negative and luminal breast cancer cell 
lines in vitro.   
TNBC cell lines MDA-MB-231 (A) or MDA-MB-468 (B) or luminal breast cancer cell 
line T47D (C) were seeded (1x105) in serum-free media in cyto-select migration chambers 
placed in complete media and treated with vehicle (control) or with Dex (dose indicated on 




was visualized by microscopic images (upper panels). Crystal violet-stained cells were 
extracted and quantified by measuring the absorbance at 590nM (lower panels). (D) MDA-
MB-231 cells were grown on tissue culture plates for 24hrs with Dex (1μM) or vehicle 
control in serum free media and collected for count of total cell number or media was 
replaced with complete media for an additional 24hrs or 48hrs. Cells were collected and 
counted. (E) MDA-MB-468 cells were grown on tissue culture plates for 24hrs with vehicle 
control or Dex (1μM) in serum free media and collected for count of total cell number or 

















Dex increases invasiveness of breast cancer cell lines in vitro.  
Previous work in bladder cancer cell lines demonstrated that Dex decreased cell invasion 
(Zheng, et al., 2012). To assess the effect of Dex on breast cancer cell lines in vitro, we 
used a cyto-select transwell invasion assay in which the chamber wells were coated with a 
collagen based extra cellular matrix. We treated MDA-MB-231 breast cancer cells with 
vehicle (control) or with increasing concentrations (0.1-10μM) of Dex. 24hrs post-
treatment cells that had migrated through the pores toward complete media were stained 
with crystal violet and imaged (Figure 2.4 A). We observed an increase in invasiveness 
with increases in Dex concentration. Cells were then lysed and analyzed by 
spectrophotometry to accurately quantify invasiveness compared to control (Figure 2.4 A, 










(A) MDA-MB-231 and (B) Hs578t were seeded in matrigel coated cyto-select migration 
chambers and treated with vehicle (control) or with Dex (at the indicated concentration for 
24hrs). Cells were stained with crystal violet and their images were taken with Leica 
microscope (upper panels). Crystal violet-stained cells were extracted and quantified by 
spectrophotometry at absorbance of 590nM (lower panels). The absorption data from 





















Dex enhances metastatic properties of breast cancer cell lines in vivo. 
To examine the effect of Dex on breast cancer cell behavior in vivo, MDA-MB-231 and 
MCF7 cells were used in an in vivo zebrafish xenograft assay. Both cell lines were injected 
into the yolk sac of the same fish and cells were able to invade outside of the yolk and form 
quantifiable metastatic tumour foci. 96hpi and 96hpt approximately 10% of fish had 
measurable tumour burden at distant sites (Figure 2.5 A-C).  Interestingly, in both cell lines, 
Dex treatment significantly increased the mean cumulative distance of the foci from the 
yolk sac (Figure 2.5 B) and at the 96hr time point the number of fish with measurable 
metastases was 4-fold higher than the DMSO control (Figure 2.5 C). Consistent with 
differences seen in in vitro assays, MDA-MB-231cells treated with Dex travelled 6-fold 
further from injection site whereas MCF7 Dex treated cells travelled 3.6-fold further than 
DMSO treated cells. MDA-MB-231 cells also had ~5% increase in final tumour burden 





Figure 2.5. Metastasis of breast cancer cells in zebrafish xenotransplants. 
(A) Representative brightfield and fluorescence images of embryos 96 hpt with either 
DMSO, 10uM Dexamethasone or 100uM Dexamethasone. Images were taken at 40x 
magnification. MCF7 cells are shown in green and MDA-MB-231 cells in red. (B) Mean 




cells. (C) Percentage of fish that had metastases outside of the yolk sac. Data represents 






















Dex treatment causes changes in inflammatory gene expression in TNBC cells but not ER+ 
cells.  
Metastases from mice implanted with TNBC cells and then treated with Dex showed 
protein enrichment of inflammatory pathways (Obradovic, et al., 2019). Here, we treated 
TNBC and ER+ cells in culture with Dex and looked at expression of inflammatory genes 
to determine if Dex directly causes upregulation of inflammatory pathways. The ER+ 
MCF7 cells had no difference in inflammatory gene expression after Dex treatment (Figure 
2.6 A). After treatment, the TNBC MDA-MB-231 had significant downregulation of IL1β, 
with both concentrations, and MMP9 after 10µM. Interestingly, Dex significantly 
increased WNT5A expression with both concentrations and increased IL6 expression after 





Figure 2.6. Differentially gene expression in breast cancer cells. 
Relative gene expression of MCF7(A) and MDA-MB-231 (B) cells after 96hours Dex 
treatment in vitro. Data represents mean ± s.d, *p<0.05, **p<0.01, ***p<0.001. n=3.  
 





Metastatic breast cancer cells present several key characteristics, namely 1) the ability to 
survive by eluding apoptosis and continuing to grow and proliferate at the primary tumour 
site; 2) The ability to invade through surrounding tissue and 3) the ability to migrate in 
circulation or within neighboring tissue (Mehlen & Puisieux, 2006). These characteristics 
may be intrinsic or acquired through mutation (Mehlen & Puisieux, 2006). Alternatively, 
these characteristics could potentially be augmented by drug treatment.  Thus, the effect of 
clinical therapies and adjuvant drugs on breast cancer cell characteristics is of clinical 
significance to the progression of metastasis. 
In chemotherapy regimens, the steroid Dex is administered in advance of 
chemotherapy to alleviate allergic and hypersensitivity reactions as well as nausea and 
vomiting in patients (Weiss et al., 1990; Wu et al., 2004). This work demonstrates that 
administration of Dex increases cell number, migratory capacity and invasiveness within 
24hpt relative to vehicle-treated control cells in vitro (Figure 2.2-Figure 2.4). Previous 
reports claim that Dex increases cell proliferation in solid cancer cells (Khan, Lopez-Dee, 
Kumar, & Ling, 2013; Zheng, et al., 2012). These previous studies used only cell viability 
assays and no counts were performed. While we did perform cell counts, neither our data, 
nor those reports, excludes the possibility that increased numbers in Dex-treated cells 
versus non-treated cells is due to increased survival and not proliferation. At most we show 
that Dex permits cells to continue dividing better than those that did not receive Dex 
(Figure 2.2 A-B). Thus, differences in cell number compared to control could be 
attributable to enhanced cell survival with Dex. Zheng et al also report that their claims of 




cyclins and CDKs (Zheng, et al., 2012). Pang et al also qualify data concerning Dex-
mediated increases in tumour size that did not show increased expression of Ki67 as most 
likely being due to an increase in survival (Pang, Kocherginsky, Krausz, Kim, & Conzen, 
2006). Furthermore, and consistent with these findings, we demonstrate that Dex decreased 
activity of caspases 3 and 7 compared to control cells (Figure 2.2 D-E). These differences 
in caspase activity may account for variance in the cell number of Dex-treated cells 
compared to control populations. Further analysis with BrdU incorporation or Ki67 
expression could give insight into this matter of concern. 
 We also demonstrate that Dex-treated cells had increased motility as evident in 
migration and invasion assays (Figure 2.3-Figure 2.4). A search of the literature shows 
several reports on Dex as reducing migration and invasion (Hayashido, et al., 1996; Piette 
et al., 2009; Shiratsuchi, Ishibashi, & Shirasuna, 2002; Zheng, et al., 2012). While these 
reports are also in other tissue types, we sought to determine whether there were alternate 
explanations for our data. One possibility is that the Dex-treated cells were surviving and/or 
proliferating faster, producing more cells on the pre-migration and pre-invasion side of the 
chambers compared to control chambers. Thus, even if equal percentages of cells migrated 
or invaded thereafter, the Dex-treated chambers would have more cells to migrate or invade 
and a selective advantage over control chambers. Another putative explanation is that while 
Dex would confer no advantage in cell number pre-migration or invasion, Dex treated cells 
would be ‘primed’ for increased proliferation or survival compared to control cells once 
they reached the complete media post-migration or post-invasion. In this model equal 
numbers of cells exist in both the control and Dex-treated cell chambers pre-migration or 




media, however, the Dex treated cells proliferate sooner and thus account for differences 
in the assay. We demonstrate that neither of these explanations can account for the 
observed data in the conditions and brief timeframe that the experiment takes place (Figure 
2.3 D-E). Given longer periods of time, however, we show that the latter explanation could 
be true and further supports our earlier report that Dex enhances survival and/or 
proliferation in breast cancer cells (Figure 2.3 D). 
 Our in vivo data supports the role of Dex in enhancing one, if not more, 
characteristics of metastatic breast cancer cells. Zheng et al ascribed increases in tumour 
mass in mice xenografts of Dex treated mice to increased survival of tumour cells resulting 
in larger tumours (Zheng, et al., 2012). It is possible that increased survival of injected cells 
in vivo contributes to final tumour burden. However, our data also shows a very significant 
increase in the distance travelled with Dex treatment and our in vitro assays support the 
ability of Dex to modulate cell motility.  
 It has been reported that Dex treatment causes upregulation of pathways involved 
in inflammation and metastasis (Obradovic, et al., 2019), specifically WNT5A and ROR1 
expression. This study only examined TNBC cells and so we wanted to determine if Dex 
would have the same effect in ER+ MCF7 cells. Interestingly, the MCF7 cells showed no 
significant difference in relative expression of any of the inflammatory genes examined 
when cells were cultured in vivo. As expected, in the MDA-MB-231 cells, Dex caused a 
significant increase in WNT5A expression, however MMP9 expression was down-
regulated. To further dissect the Dex-mediated mechanism of cell invasion, expression 
levels of other MMPs should to be examined as well as MMP levels after Dex treatment in 




upregulated which means Dex is only activating certain inflammatory pathways and though 
MCF7 cells can metastasize in vivo it must be through another mechanism than TNBC 
cells.         
Our data support that Dex can affect multiple parameters supporting metastatic 
events in vivo. Given the ubiquitous use of Dex in treating breast cancer patients with the 
most severe forms of breast cancer, further research into elucidating Dex-mediated effects 
on breast cancer cell behavior is warranted. 
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CHAPTER 3 THE TOXIC EFFECTS OF COMBINATION TREATMENT OF 


























Dexamethasone (Dex) is a corticosteroid designed as an anti-inflammatory agent and is 
often given to patients receiving chemotherapy treatments because of its very effective 
antiemetic properties (Cassileth, Lusk, Torri, DiNubile, & Gerson, 1983; C. C. Chu et al., 
2014; Levitt et al., 1993). Although the efficacy of Dex as an anti-emetic has been studied, 
the chronic adverse reactions of Dex in combination with chemotherapeutics have not been 
thoroughly studies. Reported results are mostly limited to acute effects related to energy 
levels, appetite, and sleep patterns after treatments and conclude that Dex is safe in 
combination with chemotherapy (Cassileth, et al., 1983; Levitt, et al., 1993; Roila, 1993). 
Reported side-effects of chemotherapeutics range from more mild effects like nausea, 
inflammation, etc, to very severe such as heart failure, liver toxicity, and even death, and 
although Dex was reported being administered before treatment in some studies (Burstein 
et al., 2003) it is not mentioned in most. This leads us to question if Dex had any 
interactions with these drugs to contribute to the organ toxicity observed in patients 
(Burstein, et al., 2003; Goldberg, Antin, Guinan, & Rappeport, 1986; Gottdiener, 
Appelbaum, Ferrans, Deisseroth, & Ziegler, 1981; McDonald et al., 2003; Subramaniam, 
Cader, Mohd, Yen, & Ghafor, 2013). It is critical to determine if Dex is the optimal drug 
to be given in conjunction with these drugs or if alternatives should be considered and one 
way is to model the toxicity of Dex with chemotherapy treatments in an in vivo model that 
could easily recapitulate drug toxicity.      
Zebrafish (Danio rerio) are a freshwater fish species that are easily reared in 
captivity and have been emerging as a faster, less expensive, and more high-throughput 




2006; Zakaria et al., 2018; Zon & Peterson, 2005). The transparency of the embryos allows 
easy monitoring of development and any defects that occur during drug treatment. Of 
specific importance for many drugs are the cardiotoxic and hepatotoxic effects, and assays 
in zebrafish have been established to determine toxicity in these organs (McGrath & Li, 
2008). Normally, the heart starts beating at 26 hours post fertilization (hpf) and both atrial 
and ventricle chamber precursors have formed by 48hpf (Bakkers, 2011). Conventional 
assays for determining cardiotoxicity in zebrafish embryos are measuring heartbeats/min, 
rate of arrhythmia, and size of pericardial sac. The liver is fully differentiated and 
functional by 5 days post fertilization (dpf) and assays measuring size, opacity, and yolk 
sac retention can be used to determine changes in liver metabolic activity (Augustine, 
Gagnaire, Floriani, Adam-Guillermin, & Kooijman, 2011; J. Chu & Sadler, 2009; Dai et 
al., 2014; McGrath & Li, 2008; Wilkins & Pack, 2013).  
Two cytochrome P450 (CYP) enzymes, CYP3A4 and CYP2D6 are responsible for 
the metabolism of the majority of drugs in humans and although zebrafish do contain a full 
complement of CYP genes, the suggested homolog for CYP3A4, cyp3a65 in zebrafish, has 
only about 54% sequence identity with CYP3A4  (Goldstone et al., 2010; McGrath & Li, 
2008; Poon et al., 2017). However, Tseng and colleagues (Tseng, Hseu, Buhler, Wang, & 
Hu, 2005) were able to show that Cyp3a65 is activated in the presence of xenobiotics, 
including Dex, and others have shown that it is regulated by the aryl hydrocarbon receptor, 
which regulates response to xenobiotics in mammals (Rowlands & Gustafsson, 1997; 
Vliegenthart, Tucker, Del Pozo, & Dear, 2014). Together, these studies provide evidence 




In this study we treated embryos at 48hpf or 7dpf with increasing concentrations of 
Dex in combination with either cyclophosphamide or paclitaxel to assess the embryotoxic 
effects of Dex with chemotherapeutics. We chose to examine the effects of Dex with 
cyclophosphamide and paclitaxel as they are currently widely used for treatment of both 
early and late-stage breast cancer, have different mechanisms of action (paclitaxel: micro-
tubule stabilization; cyclophosphamide: alkylating agent) (Brock & Hohorst, 1967; 
Horwitz, 1994), and were tolerated at high doses by the zebrafish. We found that many of 
the side effects reported in human cancer patients were exacerbated by the addition of Dex 
in the zebrafish embryos, especially with cyclophosphamide. These studies show the need 
to further investigate the interactions of Dex with chemotherapeutics that are given to 















Materials and methods 
Reagents 
Dex (D4902), cyclophosphamide monohydrate (cyclophosphamide) (C0768), and 
paclitaxel (T7402) were purchased from Sigma-Aldrich and diluted to their respective 
stock solutions in dimethylsulfoxide (DMSO). The final concentration of DMSO used as a 
solvent control was 0.88%. Embryo media (E3; 5mM NaCl, 0.17mM KCl, 0.33mM CaCl2, 
0.33mM MgSO4, 10-5% Methylene Blue) was made as a 60x stock solution and diluted in 
de-ionized water as needed.      
Animal care and handling 
Wild-type Zebrafish (Danio rerio) were handled in compliance with local animal care 
regulations and standard protocols of Canada. Adult fish were kept at 28.5°C and bred 
according to protocols available in the Zebrafish Book (Westerfield, 1993).  
Embryo treatment and imaging 
Zebrafish eggs were collected after fertilization and kept in E3 embryo media in an 
incubator at 33°C until ready to start treatments. 48hpf or 7dpf, the embryos were 
dechorionated with fine tip forceps, if not already hatched, and transferred to 12-well 
plates, with 20 zebrafish per well. Three independent groups of 20 fish were treated with 
each single or double drug combinations, that were diluted to their final concentration in 
E3 media (DMSO: 0.88%; dexamethasone: 5µM, 10µM, or 25µM; Cyclophosphamide: 
6mM). 3 days post treatment (dpt), 15 random embryos from each treatment group were 
imaged, without anesthesia, using a Leica M205 Stereo Microscope. Whole well images 




at 40 times magnification. Videos of the heartbeat (either 10 or 15 seconds) were taken at 
100 times magnification using the time lapse function of the LAS-AF software. At least 
two independent experiments were completed for each assay.     
Image and video analysis 
All image analysis was completed using ImageJ software. Each image was imported into 
ImageJ and changed to the appropriate scale according to the scale bar acquired from the 
LAS-AF software. The pericardial sac size, liver size, and yolk sac size were measured 
using the “Area” measure function and results were exported to Excel for further analysis. 
In the Dex and cyclophosphamide groups, some liver were undetectable and were give an 
area of “0”. Videos were imported to VLC media player and analyzed at 0.8x speed to 
accurately count the number of beats per 10 or 15 secs. This result was multiplied by a 
factor of either 6 or 4 to get beats/min. Each fish was scored qualitatively as having 
arrhythmia or normal heartrate. Arrhythmia was scored by watching the videos and was 
determined to be when both chambers of the heart were not beating at equal rates and was 
expressed qualitatively.  
RNA extraction and reverse transcription 
All 20 embryos of each treatment group were pooled together for RNA extraction and each 
treatment group had 2 independent replicates of RNA. 3dpt embryos were collected in a 
1.5mL eppendorf tube and as much of the treatment water was removed as possible. The 
TRIzol™ (15596026, Invitrogen) protocol was followed for all remaining steps of the RNA 
extraction. The QScript cDNA SuperMix (95048, Quantabio) protocol was used for reverse 




Quantitative real-time polymerase chain reaction (qRT-PCR)  
qRT-PCR was performed on a Viia-7 qRT-PCR system (Applied Biosystems) with Fast 
SYBR green fluorescent label. cDNA was diluted 1:10 in nuclease-free water. Each 
reaction contained the following: 1ul primer pairs, 4uL diluted cDNA, 5uL Fast SYBR 
green and was repeated in triplicate to account for pipetting error. Gene expression is 
reported as relative quantitation as compared to elongation factor 1-alpha (ef1α). Primer 
sequences are listed in Table S3.1.     
Statistical analysis 
Student t-test, one-way Anova with Tukey post-hoc test, or chi-squared test for trend were 
employed using GraphPad or SPSS software. All results are expressed as mean ± SEM. 




























Gene Forward (5'-3') Reverse (5'-3') References 
ef1α GAAGAAAATCGGTGGTGCTG TGGCAACAGGTGCAGTTCTA 
(McCurley & 
Callard, 2008) 
il-1β TTGTGGGAGACAGACAGTGC GATTGGGGTTTGATGTGCTT 
(Huang et al., 
2013) 
il-8 TGTTTTCCTGGCATTTCTGACC TTTACAGTGTGGGCTTGGAGGG 
(Huang, et al., 
2013) 
tnf-α ACAAGGCAATTTCACTTCCA AGCTGATGTGCAAAGACACC 
(Huang, et al., 
2013) 
il-4 GGATCCTGAATGGGAAAGGGG TTCCAGTCCCGGTATATGCT 
NCBI Primer 
BLAST design 
il-10 ACTCCACAACCCCAATCGAC GACCCCCTTTTCCTTCATCTTT 
NCBI Primer 
BLAST design 
il6 GCTATTCCTGTCTGCTACACTGG TGAGGAGAGGAGTGCTGATCC (Zhao et al., 2014) 
mmp9 CATTAAAGATGCCCTGATGTATCCC AGTGGTGGTCCGTGGTTGAG 
(Oehlers et al., 
2011) 
tlr1 ACAGAGGGACGGACGGATTA GCAGGCGTTTTAGCATCGAG 
NCBI Primer 
BLAST design 








Treatment regimen for Dex and chemotherapeutics on zebrafish embryos 
To determine the toxic effects of Dex with chemotherapeutic drugs we used a zebrafish 
embryo platform. We first determined the lethal dose for 10% of fish (LD10) and then found 
the effective concentration for 50% of tumour bulk (EC50). EC50s were obtained by 
xenotransplanting triple negative MDA-MB-231 breast cancer cells into zebrafish embryos 
and treating the fish with decreasing concentrations from the LD10 until 50% of tumour size 
was reached (Figure 3.1 A).  Toxicity was assessed by treating the fish with the EC50 dose 
for each drug, except for Dex which was treated with increasing doses, for 3 consecutive 
days beginning 48hpf as shown in Figure 3.1 B. We examined the size and morphology of 
the embryo and specifically focused on heart and liver toxicity as these are the most serious 
side effects found in chemotherapeutics. An untreated zebrafish with normal heart and liver 






Figure 3.1. Schematic of toxicity assay with zebrafish embryos. 
(A) Embryos are assayed into plates and drugs are added to each well. LD10 and EC50 
concentrations were calculated using GrapPad Software (B) Schematic of timing of drug 
additions. (C) Normal anatomy of 120hpf zebrafish. Inset shows location of heart, liver, 




Effects of Dex and cyclophosphamide treatment on embryo heart function 
We chose to treat the fish with a range of relatively low doses of Dex to determine if 
toxicity was dose dependent. It has also been shown that a low dose (10µM) of Dex 
activated cyp3a65 in zebrafish but a high dose (100µM) actually repressed basal levels of 
cyp3a65 transcription (Tseng, et al., 2005) so we wanted to make sure that the dose of Dex 
was not too high as to block metabolism in the fish. The effects of Dex and 
cyclophosphamide on size and blood flow of 3dpt embryos was determined using 
stereomicroscopy (Figure 3.2 A). Cyclophosphamide significantly decreased overall 
embryo length alone, and in combination with Dex (Figure 3.2. B). Blood flow rates were 
scored as normal or abnormal, either faster or slower than normal based on visual 
inspection of videos taken of the beating heart, and the combination treatment of Dex and 
cyclophosphamide significantly increased the number of fish with abnormal blood flow 
(Figure 3.2. C). These fish had visibly slower blood flow than DMSO treated fish. 
Cyclophosphamide has been reported to cause effects such as valve function 
failure, and congestive heart failure in patients (Burstein, et al., 2003; Goldberg, et al., 
1986; Gottdiener, et al., 1981), therefore, we assessed heart function in the embryos after 
3 days of treatment alone or in combination with Dex. Gross examination of the anterior 
area of the embryos indicated that cyclophosphamide alone did not induce a heart failure 
phenotype (Figure 3.3 A), nor did it change the heart rate (Figure 3.3 B) or the number of 
fish with arrhythmia (Figure 3.3 C) compared to DMSO treated fish. There was no increase 
in the average size of the pericardial sac indicating no significant edema (Figure 3.3 D) and 
did not increase the percentage of fish with enlarged heart sacs (Figure 3.3 E). In contrast, 




revealing an increase in the incidence of enlarged heart sacs and the average size of the 
heart sac in a dose dependent manner (Figure 3.3 A, D-E). Dex alone increased the heart 
rate (Figure 3.3 B) which is a normal response to corticosteroid treatment (Duchatsch et 
al., 2018), however the heartrate was unchanged in the combination treatment. Dex alone 
decreased the prevalence of arrhythmia with all doses compared to DMSO, and low doses 
of Dex (5 and 10µM) with cyclophosphamide also had lower incidences of arrhythmia, 
however the high dose of Dex (25µM) caused significantly more arrhythmia than any other 





Figure 3.2. Dex accentuates morphological defects in the embryo when combined with 
cyclophosphamide.  
(A) Effects of drug treatments on overall body condition of zebrafish. Images taken at 10x 
magnification, 3dpt. scale bar= 500mm (B) Graphs representing embryo length and 




Statistical analysis was performed using one-way Anova with Tukey post-hoc and Chi-









(A) Brightfield images taken at 40x magnification at 3dpt. scale bar= 500um. (B-E) Graphs 
representing (B) heart rate (C), % of fish with arrhythmia (D), pericardial area (E) and % 
of fish with enlarged pericardial sac. n=28-30 fish in 2 independent experiments. Data 
represents mean ± SEM, statistical analysis was performed using One-way Anova with 























Table S3.2. Summary of defects observed after treatment with Dex and 
Cyclophosphamide.  
Data represented as ration of affected/total number of fish or length in mm. Significance 

















Dex with cyclophosphamide altered liver appearance and yolk sac area  
Change in liver size, liver opacity, and yolk sac retention can be indications of liver toxicity 
in zebrafish (He et al., 2013) so these parameters were examined in the zebrafish treated 
with Dex and cyclophosphamide combinations. Liver size was unchanged in the DMSO, 
Dex, and cyclophosphamide single treatment groups (Figure 3.4 A-B), however the fish 
treated with Dex and cyclophosphamide together had livers that were either smaller than 
other treatment groups or undetectable. The undetectable livers were either too small to be 
seen or obstructed by the large amount of edema in the embryos and were scored as “0” 
area. The liver opacity was lower in all Dex and cyclophosphamide treatment groups, and 
again undetectable livers were given a score of “0” (Figure 3.4 C). Yolk sac retention was 
measured as the remaining area of the yolk sac at the end of the treatment period. As the 
zebrafish grows, the yolk sac is absorbed and metabolized as the embryo’s nutrient source. 
If liver function is disrupted, the yolk could be absorbed at a slower rate due to a reduction 
in lipid transport lipoproteins that are produced in the liver and needed for export of lipids 
from the yolk (He, et al., 2013; Quinlivan & Farber, 2017). Cyclophosphamide or Dex 
alone did not have a change in yolk area, however all doses of the combination treatments 
increased the yolk sac area remaining compared to the single treatment groups, ranging 
from 1.5-4 times higher yolk retention (Figure 3.4 D). This is consistent with the reduced 





Figure 3.4. Dex and cyclophosphamide combination exacerbates liver toxicity. 
(A) Representative brightfield images taken at 34x magnification at 3dpt. scale bar = 
500um. (B-D) Graphs representing (B) liver size, (C) liver opacity, (D) yolk sac area. n=at 
least 14 fish in 3 independent experiments. Data represents mean ± s.d, statistical anysos 




Gene expression profiles of Dex and cyclophosphamide treated zebrafish 
As Dex is given to patients as an anti-inflammatory agent, we hypothesized that 
inflammatory pathways would be inhibited in the Dex treatments. Cyclophosphamide is 
also described as an anti-inflammatory (Hurd, 1973) but because of the edema seen in the 
combination group there was some expectation of upregulation of inflammatory pathways 
with this treatment group. Also, cardiac edema and heart failure in zebrafish, caused by 
treatment with toxins, has previously been attributed to increases in the activity of matrix 
metalloproteinases (MMPs), especially MMP-9 (Zhang, Huang, Wang, Gao, & Zuo, 2013) 
and therefore mmp9 gene expression was also examined after treatment.  
Embryos were collected 3dpt for RNA expression analysis by qRT-PCR. 
Surprisingly, embryos treated with Dex alone had a significant increase in tumour necrosis 
factor-alpha (tnfα), interleukin 1-beta (il1β), and il10 gene expression and an increase in 
il4, il6, il8, toll like receptor (tlr1), tlr4, and mmp9 expression, though not statistically 
significant (Figure 3.5 A). In the combination treatment group, only mmp9 expression was 
significantly elevated whereas expression of the other inflammatory genes was suppressed 
to levels similar to cyclophosphamide alone (Figure 3.5 A). The heat map is shown as a 
visual representation of the clustering of expression of genes by average linkage and clearly 
depicts the expression differences between the treatment groups with Dex upregulating the 
ILs, TLRs, and tnfα and Dex in combination with cyclophosphamide upregulating mmp9 








Figure 3.5. Dex induces expression of inflammatory genes in zebrafish. 
(A) qRT-PCR data of embryos after treatment with Dex and cyclophosphamide. Graphs 
represent triplicate PCR reactions from two independent experiments. Y-axis represents 
relative quantitation of gene normalized to ef1α. Data presented as mean ±SEM, statistical 
anaysis performed using One-way Anova with Tukey post-hoc, * p<0.05, **p<0.01. (B) 




















The combination of Dex and paclitaxel has no significant cardiotoxic or hepatotoxic 
effects: 
Paclitaxel, another common chemotherapeutic, has reported side effects of changes in heart 
rate and lowered blood flow (Florescu, Cinteza, & Vinereanu, 2013). To determine, 
whether Dex causes also heart failure when combined with drugs other than 
cyclophosphamide, embryos were treated with combinations of Dex and paclitaxel. 
Embryos were first treated for 3 days starting at 2dpf. When examining the embryos at 
high magnification there were only subtle visible differences in heart and liver morphology 
and the enlarged heart sacs were not seen (Figure 3.6 A). Again, Dex significantly 
increased the heartrate of the embryos and this effect was conserved when Dex was 
combined with paclitaxel (Figure 3.6 B) but the pericardial area was not significantly 
affected (Figure 3.6 C). There was also no significant arrhythmia or change in blood flow 
with any of these treatments (not shown). While examining the organ development of the 
embryos, it was observed that the livers were significantly smaller with Dex, alone and in 
combination with paclitaxel, than in the DMSO treated group (Figure 3.6 D). The retention 
of the yolk sac, however, was significantly decreased with Dex treatment alone and not in 
the combination treatments (Figure 3.6 E). Because the embryo liver is more differentiated 
after 5dpf, we added a treatment schedule of treating every 24hrs for 3 days starting at 7dpf 
when the fish are in the larval stage (Figure 3.7 A). Treating larval zebrafish with the same 
concentration resulted in paclitaxel having larger livers than the other treatment groups 
(Figure 3.7 B and C) but Dex alone and Dex with paclitaxel had no effect on liver size. 





Figure 3.6. Effects of Dex and paclitaxel on organ toxicity.  
(A) brightfield images taken at 40x magnification of embryo at 96hpf. (B) Graphs 
representing embryo heartrate, (C) pericardial area, and (D) Liver area. Data represents 
mean ± SEM, statistical analysis performed using One-way Anova with Tukey post-hoc,  







Figure 3.7. Effects of Dex and Paclitaxel on the liver at 10dpf. 
(A) Schematic of drug treatment schedule (B) brightfield images of embryo at 10dpf taken 
at 32x magnification. (C) Graph representing liver area (µm2), (D) Graph representing yolk 
sac area (µm2x103). Data represents mean ± s.d, statistical anysis performed using One-










Zebrafish have long been used for drug toxicity studies since they are completely 
transparent in early development, providing an excellent platform to study the side effects 
of drugs in vivo. Our studies focused on the effects of drug combinations on embryo and 
larval zebrafish organs, which have shown drug toxicity profiles similar to adult human 
organs (Dai, et al., 2014; Wilkins & Pack, 2013; Zakaria, et al., 2018; Zhu et al., 2014). 
We specifically focused on determining the effects of the anti-emetic steroid Dex when 
used in combination with cyclophosphamide or paclitaxel, two drugs used in cancer 
treatment. Our goal was to determine if side effects typically seen with chemotherapy 
patients are exacerbated by the addition of Dex.  
When Dex was added simultaneously with cyclophosphamide or paclitaxel our 
work showed that Dex alters the effects of the drugs used. The fish that received both 
cyclophosphamide and Dex had phenotypes indicative of heart failure with significantly 
larger pericardial sacs, more edema, and abnormal blood flow (Figure 3.2. and Figure 3.3). 
These fish also had much smaller livers than other treatment fish and more yolk retention 
which suggested a decrease in absorption by the embryo and linked to a decrease in liver 
function as the lipoproteins needed for yolk lipid export are produced in the liver (He, et 
al., 2013; Quinlivan & Farber, 2017) (Figure 3.4). Further investigation is required to 
determine if the yolk sac retention is in fact due to a disruption of liver function and 
metabolism, due to overall systemic metabolic problems, or that these fish have slower 
rates of activity and require nutrients at a slower rate.    
Gene analysis showed that though Dex is used as an anti-inflammatory, Dex 




combination of Dex and cyclophosphamide did not activate the same inflammatory 
pathways but did show a significant increase in mmp9 expression. It has previously been 
shown that treating developing zebrafish embryos with Dex alone can cause altered 
developmental morphology through increases in MMP activity (Hillegass, Villano, 
Cooper, & White, 2008), however there has been no previous study showing the same 
upregulation in combination treatments. As well, inhibiting Mmp-9 activity reverses 
cardiac toxicity in fish treated with polycyclic aromatic hydrocarbons (Zhang, et al., 2013). 
Increased edema in humans after ischemic stroke and cerebral hemorrhage has been 
attributed to MMP-9 activity (Abilleira et al., 2003; Castellazzi et al., 2010; Rosell et al., 
2006). In our study, upregulation of mmp9 expression in zebrafish was amplified in the 
presence of cyclophosphamide treatment which we suggest led to the increases in cardiac 
edema that was observed. Future work to resolve whether Mmp-9 inhibitors can 
circumvent cardiotoxicities in animal models undergoing cyclophosphamide and Dex 
treatment would be the next direction for this work.    
When combined with paclitaxel, however, Dex did not have the same cardiotoxic 
or hepatotoxic effect as with cyclophosphamide, perhaps due to the discrepancy in dosing 
of the two drugs or the differences in mechanisms of action. Previously publish research 
does show a disparity between the effects of Dex in combination with different drugs. For 
example, a previous study determined that Dex interacted negatively with the 
chemotherapy drug, doxorubicin, by elevating glucose blood levels and making 
cardiomyocytes more sensitive to doxorubicin side effects (Di Biase et al., 2017). On the 
other hand, mice pretreated with Dex were protected from liver toxicity caused by 




need to examine the toxicity of Dex with individual chemotherapy drugs that are 
simultaneously given to patients and to ensure minimal negative interactions with the 
drugs. The use of Dex as an antiemetics needs to be studied further in mammalian models 
and clinical trials to make sure that the patients are not unnecessarily sacrificing quantity 
of life for quality.  
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CHAPTER 4 TESTING THE EFFICACY OF NATURAL HEALTH PRODUCTS 

























Many epidemiological studies and experimental trials have shown that there is a 
relationship between prolonged oxidative stress in the body and the development of 
multiple health conditions, such as cardiovascular, renal, mental health, premature ageing, 
as well as cancer (Liguori et al., 2018; Salminen, Ojala, Kaarniranta, & Kauppinen, 2012; 
Young & Woodside, 2001). Oxidative stress has also been shown to interfere with cancer 
treatments by inhibiting apoptosis (Shacter, Williams, Hinson, Senturker, & Lee, 2000). 
On the other hand, clinical trials with antioxidants have been largely ineffective, with many 
showing even harmful effects (Bjelakovic, Nikolova, Gluud, Simonetti, & Gluud, 2007; 
Goodman, Bostick, Kucuk, & Jones, 2011; Steinhubl, 2008; Zhang et al., 2008). Halliwell 
(2000, 2013) has described the discrepancy between epidemiological and experimental 
studies and clinical trials as the “antioxidant paradox” and this has continued to be 
discussed when treating diseases that are thought to arise from oxidative stress (Biswas, 
2016; Bonner & Arbiser, 2014; Halliwell, 2000, 2013).  
 Oxidative stress is the result of an imbalance of the body's ability to readily detoxify 
reactive intermediates (free radicals) or to repair the resulting damage caused by these 
intermediates. Such disturbances in the normal state of cells can cause toxic effects through 
the production of peroxides and free radicals that damage all components of the cell, 
including proteins, lipids, and DNA (Pham-Huy, He, & Pham-Huy, 2008). To combat 
oxidative stress, the body has evolved natural defense systems. The major antioxidant 
enzymes directly involved in the neutralization of free radicals are superoxide dismutase, 
catalase, glutathione peroxidase and glutathione reductase (Genestra, 2007; Halliwell, 




2004; Young & Woodside, 2001).  Inflammation, on the other hand, is part of a complex 
protective response involving immune cells, blood vessels, and molecular mediators. 
Inflammatory responses can be triggered due to infections, tissue damage after injury, as 
well as exposure to irritants (Coussens & Werb, 2002; Demaria et al., 2010; DeNardo & 
Coussens, 2007). With increasing understanding of the oxidative pathways and 
inflammation, undeniable evidence has been collected to show the tightly linked 
relationship between the two (Figure 4.1) and their combined role in maintaining body 




















Figure 4.1. Relationship between oxidative stress and Inflammation. 
Oxidative stress and inflammation are very closely linked. Whether inflammation or 














It is, then, not hard to imagine how persisting oxidative stress in the body leads to 
the same health conditions as chronic inflammation. Many studies show that oxidative 
stress can activate inflammatory pathways such as the necrosis factor kappa B (NFκB), 
signal transducer and activator of transcription 3 (STAT3), and interleukin-8 (IL-8) 
signaling (Barry et al., 2009; DeForge et al., 1993; Kratsovnik, Bromberg, Sperling, & 
Zoref-Shani, 2005). Given such an integral connection between the two processes, an 
antioxidant paradox arises. For any formula to reproducibly perform as an antioxidant in 
the human body, it must have the ability to modulate the immune system as well as balance 
oxidative stress.  
The optimal research model to determine a compound’s efficiency as an anti-
inflammatory and antioxidant would be an in vivo animal model with an intact immune 
system. Zebrafish have been used in research since the early 1960s, but its success as a 
human physiological model organism was precipitated by its genome sequencing in 2013 
(Howe et al., 2013). The zebrafish has a very similar genetic structure to humans and has 
complementary gene counterparts to 82% of all the human disease genes known to date 
(Howe, et al., 2013; Strynatka, Gurrola-Gal, Berman, & McMaster, 2018; Varga et al., 
2018). They also have very similar organ structures and share similarities in physiology 
with humans (Seth, Stemple, & Barroso, 2013). Today thousands of research laboratories 
all over the world are modeling human pathologies to understand the mechanisms of 
disease and how it occurs in humans. We therefore used the zebrafish model as an efficient 
and affordable way to decipher the effect of compounds on disease processes. 
Many anti-inflammatory drugs have severe side effects, such as edema, heart failure 




Nowak, 2016; Duque Ede & Munhoz, 2016; Polderman et al., 2018; Sriuttha, 
Sirichanchuen, & Permsuwan, 2018) which is why there has been an increased interest in 
finding over-the counter, natural health products (NHPs) that can be taken at lower doses 
and will not cause severe side effects.  
Lifestyles’ Nutria plus capsules are a powerful antioxidant supplement formulated 
to be taken as a daily supplement that will defend against inflammation and oxidative 
stress. Nutria plus contains a variety of plant-based ingredients such as green tea, grape 
seed and amla extracts, and other vitamins and minerals to provide maximum free radical 
neutralizing properties. Extensive proprietary research and systematic scientific scrutiny 
went into the design and development of Nutria plus (unpublished, proprietary). The 
formulation was then evaluated for all the claims through direct physiological 
measurements in a live zebrafish model that is a close mimic to human physiology.  
Nutria plus was developed with this pioneering concept of balancing oxidative 
stress alongside inflammation in the body. Our preliminary results show that Nutria plus 
has the potential to prevent damage from UV and heal tissue that is already damaged due 
to mild UV exposure, improve tissue repair and regeneration, and prevent abnormal 










Materials and methods 
Composition and formulations 
The new formulation for Nutria plus was an evolution of an existing formula called Nutria. 
Nutria was a sister antioxidant formulation to LifeStylesTM Intra product that was designed 
to support all the biological systems of the body (Lifestyles, 2019). Acenzia Inc. developed 
two Nutria plus formulas - one with high SelenoExcell (HSe) and the other with low 
SelenoExcell (LSe). Each ingredient in both Nutria plus formulas has been carefully 
selected based on previous studies of their antioxidant and anti-inflammatory capacities as 
referenced in Table 4.1. The daily dosages of each ingredient as well as their potential 
benefits are listed in Table 4.1. The HSe formulation was registered with Health Canada 
with a Natural Product Number (NPN) of 80081633. Other non-medicinal ingredients used 















Ingredient Potential Benefits and References Daily Dosage 
(mg/day) 
HSe LSe 
SelenoExcell Reduces oxidative stress biomarkers, a measure of healthy 
aging and reduced risk for chronic illness and certain cancers 
(El-Bayoumy et al., 2002) 160 40 
Grape Seed 
Extract 
Proanthocyanidins from grape seed extract possess potent 
free radical scavenging abilities (Bagchi, Swaroop, Preuss, & 
Bagchi, 2014; Stankovic et al., 2008)  110 110 
Green Tea Extract Strong antioxidant. Rich in polyphenols, predominantly 
catechins (Carrizo, Gullo, Bosetti, & Nerin, 2014). Skin 
photoprotective effects. Skin photoprotection by natural 
polyphenols: anti-inflammatory, antioxidant and DNA repair 
mechanisms (Nichols & Katiyar, 2010). 100 140 
Spirulina Powder Antioxidant with immunomodulating activity (Finamore, 
Palmery, Bensehaila, & Peluso, 2017). 
90 100 
Ascorbic Acid Also known as Vitamin C, ascorbic acid is a powerful 




Has antioxidant, immunomodulatory and anti-inflammatory 




Contains beta-carotene, a precursor of Vitamin A which is a 
strong antioxidant (Kartha & Krishnamurthy, 1977; Palace, 







Has anti-inflammatory and antioxidant effects (Rose, 
Whiteman, Moore, & Zhu, 2005). 
40 40 
Red Beet Root 
Extract 
Betalain pigments demonstrate antioxidant, anti-
inflammatory and chemo-preventative activity both in vitro 




Sulphur containing glucosinolates show potential anti-





Phenolics from prunes show high antioxidant activity 




Has strong antioxidant activity (Tibullo et al., 2017).   
20 20 
 Total 740 750 
 
Table 4.1. Selection of active ingredients and quantities for two selected formulas of Nutria 








In vitro antioxidant capacity assay 
A 0.4mol/L glacial acetic acid solution (pH 5.8) was made in sodium acetate buffer 
(Reagent 1). A 37.5ml of a 30mmol/L sodium acetate solution was mixed with 462.5ml of 
a 30mmol/L acetic acid solution (pH 3.6). 324.3μl of a 30% H₂O₂ solution was added. To 
51ml of this solution, 280mg 2,2′-Azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) 
diammonium salt (ABTS) (Sigma; A1888) was added and incubated for 1hr. When 
solution was ready, a characteristic blue-green colour appeared (Reagent 2).  
For each dry powdered Nutria ingredient or complete capsule formula (HSe and 
LSe), approximately 100mg powder was transferred into a 50ml tube and resuspended with 
ultrapure water to 10mg/ml. The tubes were vortexed and placed on a tube roller for 20min, 
and centrifuged at 2,400g for 10min. The supernatant was immediately removed thereafter 
and the pellet (if present), resuspended in another 10ml ultrapure water and place on tube 
roller for another 20min. The centrifugation step was repeated, and the supernatant 
combined to make 5mg/ml solution. Any pellet remaining was resuspended in ethanol to 
10mg/ml and placed on the tube roller for 20min, and then centrifuged at 2,400g for 10min 
to obtain a 10mg/ml ethanol extract.  
The T92+ ultra-violet (UV) spectrophotometer was set up with the “Kinetics” 
Method to measure wavelength at 660nm for 5 min. The instrument was zeroed using 1.6ml 
of Reagent 1 in a 2 or 4ml disposable cuvette. A standard was obtained using 0, 0.25, 0.5, 
0.75 and 1mmol/L ascorbic acid solution. 20μl of each standard was added to the cuvette. 
While cuvette was in the cell holder, 160μl of Reagent 2 was added to the cuvette and 
mixed once. At the same time, the absorbance reading was recorded at the 5th min. The 




results for the standards, the standard curve was plotted on a spreadsheet. Multiple standard 
curves were recorded across several experiments and all suitable data points were used for 
the creation of the best fit line. The equation of this line was used to determine the ascorbic 
acid equivalent for each sample across experiments performed on different days. 
Zebrafish husbandry and embryos 
Zebrafish Research Facility as well as the Animal Care Committee in Acenzia Inc. is 
certified through Ontario Ministry of Agriculture, Food and Rural Affairs (OMAFRA) and 
all protocols used in the laboratories are monitored by the Animal Health and Welfare 
Branch, OMAFRA. Fishes are housed and maintained using Tecniplast ZebTec system 
with a controlled day-night (14hr light/10hr dark) light cycle. Embryos were obtained from 
natural spawnings and developmental stages were reported as hours post-fertilization (hpf) 
at 28.5°C.  
Tail fin amputation assay 
Zebrafish larvae were randomized and immersed in 1µg/ml green tea equivalent (GTE) of 
the Nutria plus HSe and LSe formula or control (0.5% dimethylsulfoxide (DMSO)) in 
filtered system water for 1hr prior to tail fin amputation. Larvae were immersed in tricaine 
solution, then placed in petri dish with a drop of tricaine to prevent dehydration. Using a 
sharp syringe needle, the tail fin was cut right after the tip of the tail. Larvae were imaged, 
then placed back into its appropriate treatment solution in a 6-well plate at 35°C. The day 
after amputation, approximately 75% of the previous day’s solution was replaced with 
freshly prepared drug solutions. 
Immediately following amputation and 2 days later, larvae were placed on a 1% 




was performed on tail fin images immediately after amputation and after two days of 
treatment post amputation. Similar measurements were performed on tail fin images on 
non-amputated control larvae that were incubated exactly the same way as the tail fin 
amputated larvae. The control larvae were used to measure the growth of the fins during 
normal larval development.  
To measure a consistent area of the fin, the entire area of the fin beyond the cloacal 
notch was measured. Area of fins were measured (in arbitrary units) using ImageJ 
(National Institutes of Health). Analyzing fins of larvae without any fin amputation, we 
calculated the normal growth rate (in terms of % growth) of the fins. These fish were 
normalized to show no regeneration. Percent regeneration was calculated as follows: 
Day 0 metric = Area amputated fin area / Area of non-amputated fin 
Day 2 metric = Area of missing fin (at day 2) / Area of fin measure in non- 
amputated control fish (at day 2) 
Percent Regeneration = 100 x [(Day 0 metric) - (Day 2 metric)] 
UV exposure assay 
At 3 days post fertilization (dpf), larvae (n=10) were treated with either 1μg/ml GTE of 
Nutria plus HSe or LSe in 0.5% DMSO for 24hrs. Control larvae were treated with 0.5% 
DMSO only. At 4dpf, the media was removed, and the half of the experimental larvae were 
treated with 19s of UVC (approximately 25mJ/cm²) and the other half received no UV 
exposure. Fresh solutions of Nutria plus were added back to the larvae and they were kept 
at 28.5°C for 24hrs. At 5dpf, the larvae were stained with 5μg/ml Acridine Orange (AO) 




Fish larvae were placed in tricaine solution and imaged on a 1% agarose bed under 
the Leica stereomicroscope using a GFP filter. The fin of the fish was analyzed using 
ImageJ’s Integrated Density measure. First, the fin area was outlined and then the area and 
the Raw Integrated Density was measured. DNA damage per unit area was measured as 
[Pixel of Raw Integrated Density / Area of Fin]. 
Angiogenesis assay 
1dpf embryos were incubated in fresh 150μg/ml trypsin in a 28.5°C incubator for 
dechorionation. Approximately 150-200 HCT-116 colorectal cancer cells were stained 
with Vybrant DiI dye and injected into the yolk sac of dechorionated embryos. They were 
then randomized into Nutria plus HSe, Nutria plus LSe or DMSO control groups of at least 
50 embryos each. An additional group of larvae that did not receive cell xenografts was 
included. The next day, embryos with cells that were improperly injected were eliminated. 
At 3dpf, larvae were anesthetized in 168mg/L tricaine and only fishes with a clear 
tumour bolus in the yolk sac were selected for fixation. Larvae were then fixed in 4% 
paraformaldehyde at room temperature for 3hrs. Samples were next washed twice with 
0.1% Tween-20 in PBS (PBST) and dehydrated in successive washes of 25%, 50%, 75% 
and 100% Methanol in PBST. Next, the samples were rehydrated in successive washes of 
75%, 50%, 25% Methanol and finally PBST. Samples were then equilibrated in alkaline 
phosphatase buffer (100mM NaCl, 50mM MgCl2, 100mM Tris pH 9.5, 0.1% Tween-20 in 
ultrapure water) at room temperature for 30min. Next, samples were stained in alkaline 
phosphatase buffer containing 110μg/ml nitro blue tetrazolium (Promega; S3771) and 
55μg/ml 5-bromo-4-chloro-3-indolyl-phosphate (Promega; S3771) on a 35 °C heat block 




Samples were then rinsed 2 to 4 times in stop buffer (0.25mM Ethylenediaminetetraacetic 
acid in phosphate buffered saline, 0.1% Tween). Samples were then re-fixed in 4%  
paraformaldehyde at 4ºC overnight. The next day, samples were transferred to 80% 
glycerol in stop buffer for long term storage at 4ºC. 
Subintestinal vessels of each larva were imaged using the Leica M165 FC 
microscope on an agarose plate. For each larva, the total area, (excluding the caudal 
cardinal vein) of the subintestinal vessels were outlined with the freehand tool and 
measured using ImageJ. The average of the total areas measured for each group was 



















In vitro antioxidant capacity of Nutria plus ingredients 
Nutria plus was derived from the formulation of Intra, an NHP supplement, and should 
have minimal antagonizing biological effects. Each component of the formulation was 
therefore evaluated for their contribution towards the antioxidant capacity of the 
formulation and how each component interacted together as a formulation with Intra. Table 
2 shows the Total Antioxidant Capacity (TAC) of each selected formula of Nutria plus and 
how they performed in combination with Intra. The calculated TAC is the predicted value 
based on the sum of the activity of each individual ingredient. Nutria plus as a formula (as 
shown in Table 4.2 A) had a far higher TAC in comparison to the calculated cumulative 
activity. The components of Nutria plus are working together to enhance the TAC. 
Similarly, Nutria plus along with Intra had higher TAC (as shown in Table 4.2 B) in 






Table 4.2. Interaction of Nutria plus with Intra. 
(A) Percentage increase in observed Nutria Plus TAC as compared to calculated (B) 











Increase in activity 
Intra 297.192  
Nutria plus (HSe) Calculated 593.25145  
Nutria plus (HSe) Observed 880.0122 32.59% A 
Nutria plus (LSe) Calculated 766.1521  
Nutria plus (LSe) Observed 906.1624 15.45% A 
Nutria plus (HSe) + Intra [in ratio] Calculated 1177.2042  
Nutria plus (HSe) + Intra [in ratio] Observed 1489.3852 20.96% B 
Nutria plus (LSe) + Intra [in ratio] Calculated 1203.3544  





Evaluating the toxicity of Nutria plus in zebrafish embryos 
To evaluate the biological effects of the Nutria plus formulation in the zebrafish model, we 
needed to estimate the best dosage that should be used for testing in zebrafish. We used the 
highest tolerated dosage with minimal toxicity (LD10 - lethal dose 10%). As Green Tea 
Extract had the lowest LD10 (approximately 1 µg/ml) among the tested ingredients (data 
not shown), we decided to use 1 µg/ml of GTE for all zebrafish studies.  
Nutria plus prevents cellular death due to sun exposure 
UV radiation from the sun consists of UVA (315-400nm), UV-B (280-315nm) and UVC 
(200-280nm). Although UVC is absorbed by the ozone layer, the photochemistry of direct 
DNA damage caused by UVB and UVC are similar - cyclobutane pyrimidine dimers and 
pyrimidine 6-4 pyrimidone photoproducts (Cleaver, 2006). UV can also cause indirect 
DNA damage through the production of reactive oxygen species (de Jager, Cockrell, & Du 
Plessis, 2017). To evaluate the role of Nutria plus in protecting the skin from the deleterious 
effects of sun exposure and UV damage, we used a zebrafish low dose UVC exposure 
model. Zebrafish larvae show a rapid increase in cellular damage and apoptosis when 
exposed to low dose UVC and it can be visualized through staining the larvae with AO 
after irradiation. Figure 4.2 A and top panel of B show that with UV exposure, larvae 
sustained significantly more DNA damage and hence cellular death per unit area compared 
to larvae that were not exposed to UV. Importantly, this damage was significantly reduced 
in larvae that received Nutria plus, demonstrating the beneficial effects of Nutria plus in 





Figure 4.2. Nutria plus prevents cellular death due to sun exposure. 
(A) Normal larva stained with AO. (B)  Larva exposed to UV and stained with AO. (C) 
Graph representing the measured stain intensity in the tail fins of larvae in each treatment 
as measured using ImageJ RawIntegrated Intensity. SEM representing at least n=10 in each 
treatment. HSe=high SelenoExcell concentration, LSe=low SelenoExcell concentration, 










Nutria plus enhances tissue repair after injury 
In humans, distinct inflammatory responses at the site of injury help with tissue 
regeneration (Cooke, 2019; Jiang & Liao, 2010). The first step is initial defense against 
infection and then eventual resolution of inflammation for proper regeneration. An intricate 
balance regulates this process, and if imbalanced, can form scar tissue. Zebrafish tail-fin 
amputation model has been used to demonstrate how this process works (Li, Yan, Shi, 
Zhang, & Wen, 2012; Ouyang et al., 2017; Petrie, Strand, Yang, Rabinowitz, & Moon, 
2014; Thummel, Ju, Sarras, & Godwin, 2007). Here, we used a similar zebrafish model to 
demonstrate the beneficial immunomodulatory effects of Nutria plus. Larvae that received 
Nutria plus HSe and LSe, before and following amputation of the tail fin, showed an 
increase, roughly 8% and 20%, respectively, over control area of regenerated tissues 
demonstrating the beneficial effects of Nutria plus during wound healing and tissue repair 















Figure 4.3. Nutria plus enhances tissue repair after injury. 
(A) Normal growth of larval tail fin over two days of observation. Days post amputation 
(dpa) does not apply for unamputated larvae so corresponding dpf has been shown in the 
bracket. (B) Left panel is showing normal growth along with regeneration of amputated 
larval tail fin. The middle panels and right panels are showing growth along with 
regeneration of amputated larval tail fin in presence of Nutria plus formulations. (C) 
Graphical representation of the observed fin regeneration in control, Nutri plus HSe and 







Nutria plus prevents abnormal cellular growth 
Angiogenesis is the process in which new vessels are formed from pre-existing ones. Such 
new vessel formation is developed locally to promote increased supply of nutrients to 
growing tissues. Angiogenesis is a crucial event during the proliferation of cancer cells in 
the body, as tumour tissues require nutrients and oxygen to grow beyond a particular size 
(generally 1–2mm3) to develop into cancer (Carmeliet, 2005; Nishida, Yano, Nishida, 
Kamura, & Kojiro, 2006; Ono, 2008).   
Localized inflammation due to growth of tumour cells triggers the process of 
angiogenesis. It has been shown using zebrafish that xenografts of tumour tissues result in 
new and abnormal increase in vessel formation, mimicking the process of angiogenesis 
observed in humans (Chiavacci et al., 2015; Nicoli & Presta, 2007). To evaluate the role 
of Nutria plus as an anti-inflammatory and specifically as an angiogenesis inhibitor, we 
implanted tumour cells into the yolk sac of zebrafish larvae and examined if Nutria plus 
could reduce tumour-induced angiogenic vessel growth. Normal angiogenesis was 
observed in zebrafish with no cells and no Nutria (Figure 4.4 A). With the addition of 
cancer cells, the area of vein formation increased (Figure 4.4 B), however with the addition 
of Nutria plus HSe and LSe, the area of vein formation was decreased back to control levels 










Figure 4.4. Nutria plus prevents abnormal cellular growth. 
Representative pictures of larva with subintestinal vein formation with (A) no treatment 
and no cells, (B) cancer cells are present. (C) Nutria plus HSe treatment and cancer cells 
implanted, and (D) Nutria plus LSe treatment with cancer cells present. (E) Graph showing 
the quantitative measurement of the area of subintestinal vein in square inches. SEM 


















Mechanism of action 
After extensive research, we developed a biological activity pathway map logically 
explaining the expected mechanism of action of the product (Figure 4.5). Nutria plus is 
designed to influence both oxidative stress and unwanted inflammation. UV exposure, 
along with increased oxidative stress in the body, leads to cellular ageing through DNA 
damage. Persisting inflammation in the body impairs tissue repair and regeneration after 
injuries as well as persisting inflammation promotes abnormal cell growth, which can lead 













Figure 4.5. Mechanism of action of Nutria plus.  
Nutria plus is designed to influence both oxidative stress and unwanted inflammation. UV 
exposure, along with increased oxidative stress in the body, leads to cellular ageing through 
DNA damage. Persisting inflammation in the body impairs tissue repair and regeneration 
after injuries as well as persisting inflammation promotes abnormal cell growth, leading to 
diseases such as cancer. Nutria plus has been shown to inhibit DNA damage, abnormal cell 










Conventional treatments for acute and chronic inflammation include, as examples, 
dexamethasone and nonsteroidal anti-inflammatory drugs which are very commonly 
prescribed worldwide. Although effective in treating inflammation, these types of drugs 
are notorious for causing serious side effects especially when used over a long period of 
time (Fraiser, Kanekal, & Kehrer, 1991; He et al., 2013; Kanekal, Fraiser, & Kehrer, 1992; 
Sriuttha, et al., 2018).           
There is a growing trend to use NHPs for medicinal purposes to try to reduce the 
incidence of side effects. NHPs are becoming more popular, especially for the treatment of 
inflammation and as anti-cancer agents in different types of tumours, for example recent 
studies have used Burdock (Arctium lappa) extract to treat melanoma tumours in mice and 
pitcher plant (Nepenthes thorellii x (ventricosa x maxima)) extracts as an anti-cancer agent 
for breast cancer cells (Nascimento et al., 2019; Ou-Yang et al., 2019). There is also 
evidence of NHPs preventing oxidative stress and preventing hepatotoxicity after treatment 
with doxorubicin, a chemotherapeutic (Song et al., 2019).  
In this study we used a zebrafish model to examine the effectiveness of Nutria plus, 
an NHP, as an anti-inflammatory and antioxidant. Using zebrafish as a model system is an 
affordable option for in vivo studies, especially in an industrial research setting that requires 
less expensive research methods. Using zebrafish to test NHPs has been well established 
(Kao et al., 2010; Pitchai, Rajaretinam, & Freeman, 2019; Yin et al., 2018) so this was an 
appropriate model to determine the efficacy of Nutria plus products.    
Because Nutria plus is a sister formula to Intra, it was first imperative to determine 




Nutria plus HSe was shown to have approximately double the TAC when compared to 
Intra alone, and interestingly had 32.59% higher antioxidant potential than the calculated 
or predicted TAC, suggesting the ingredients work together as agonists to be more efficient 
antioxidants. Nutria plus LSe was less efficient but still had a 15.45% increase from the 
calculated TAC. When combined, Nutria plus and Intra were able to increase the TAC by 
roughly 50% meaning the ingredients are not antagonizing each other.  
To determine if Nutria plus was able to prevent UV damage and repair any damage 
that has already occurred, embryos that were exposed to UV with and without Nutria plus 
treatment were stained with AO, which is a dye that will intercalate with damaged DNA in 
living cells to fluoresce green (dead cells will fluoresce red) and can be used in live imaging 
of DNA damage and cell death in zebrafish  (Kao, et al., 2010; Paquet et al., 2009; Tucker 
& Lardelli, 2007). After UV damage, Nutria plus had significantly less AO staining than 
fish without Nutria plus treatment, as shown by a significant decrease in green fluorescence 
in the tail region of the embryo. This is suggesting that Nutria plus pretreatment is 
preventing DNA damage or even stimulating repair of damage that was induced by UV. 
To determine if Nutria is in fact preventing damage or only helping to repair existing 
damage, it is necessary to have a study with embryos that are not pre-treated with Nutria 
plus but do receive it after damage. It is also a possibility that Nutria plus is causing the 
damaged cells to undergo apoptosis which would show an increase in the AO fluorescing 
red instead of green, so this is something we are looking into further.  
Inflammation and oxidative stress decrease the body’s ability to repair tissue 
(Coussens & Werb, 2002; Das et al., 2015; Schafer & Werner, 2008), so we wanted to 




acute injury. Nutria plus was able to increase the rate of regeneration of tail tissue after tail 
amputation over embryos that had no Nutria plus treatment. Interestingly, the Nutria plus 
LSe was able to regenerate at a faster rate than Nutria plus HSe, suggesting that a higher 
dose of SelanoExcell is not more beneficial for tissue regeneration. Nutria plus was also 
able to decrease the area of angiogenesis into the yolk when cancer cells were engrafted 
but again the Nutria plus LSe was more effective than the HSe formulation. Given that the 
HSe and LSe formula seem to be more effective with different processes it is necessary to 
further investigate whether only one formula should be used ubiquitously or if formulas 
should be personalized depending on medicinal need. 
This preliminary research has shown potential for Nutria plus to be effective in 
combating the negative effects of oxidative stress and inflammation. We caution that more 
research still needs to be completed to determine if Nutria plus could be a replacement for 
current anti-inflammatories, which often have harsh side effects, and whether it will be 
effective for combating long term inflammation and oxidative stress. We also note that any 
potential interaction with the effectiveness of chemotherapy drugs is an essential level of 
testing that would need to be completed in pre-clinical models and then carefully tested in 
randomized control clinical settings prior to any recommendations for patient use.    
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Breast cancer remains the second leading cause of cancer deaths in Canadian women (Bray 
et al., 2018) with the late, metastatic stage being considered incurable. Breast cancer 
initiates with hyperproliferation of mammary luminal cells to form a primary hyperplastic 
nodule. These cells become highly disorganized and some can gain the ability to invade 
through the basement membrane (Feng et al., 2018; Mittal, Brown, & Holen, 2018) which 
begins the progression to metastatic disease.  
Metastasis is a series of processes that allows cells to migrate away from the 
primary tumour site and colonize distal organs. These processes include invasion through 
the extra cellular matrix (ECM) and entrance into the blood stream, extravasation and 
colonization of the distal site (Polyak, 2007). As discussed by Bill and Christofori in their 
review of metastatic cell processes, the most favoured explanation for cell metastasis is the 
epithelial-to-mesenchymal transition (EMT) which is the transformation of the cells from 
an epithelial phenotype to a more stem-like mesenchymal cell (Bill & Christofori, 2015). 
Characteristics of cells undergoing EMT include loss of E-cadherin expression and gain of 
N-cadherin, nuclear localization of β-catenin, and an overall change in morphology 
(Christiansen & Rajasekaran, 2006). While EMT is a demonstrated event during 
metastasis, there is ample data in breast and other cancers to support that EMT is neither 
required nor sufficient for metastasis to occur (Fischer et al., 2015; Lou et al., 2008; Zheng 
et al., 2015).  
Proper cell-ECM interactions are critical for normal mammary gland development 
but are implicated in breast cancer progression and metastasis (Muschler & Streuli, 2010). 




fibronectin, etc) and induce signaling cascades involved in cancer processes. There is some 
controversy whether these integrin units help prevent or contribute to metastasis. In MCF7 
breast cancer cells β1-integrin can increase E-cadherin expression to prevent metastasis 
(Parvani, Galliher-Beckley, Schiemann, & Schiemann, 2013; Truong et al., 2014). 
However, in MDA-MB-231 metastatic breast cancer cells, invasion and migration was 
significantly inhibited using both β1-integrin blocking antibodies and extracellular signal-
regulated kinase (ERK)1/2 or mitogen-activated protein kinase kinase (MEK) inhibitors 
(Mierke, Frey, Fellner, Herrmann, & Fabry, 2011).  
Early signs of breast cancer, such as hyperplasia and disorganization, are present in 
the alveolar structures and can be recapitulated in vitro using a well developed 3-
dimensional (3D) overlay technique that allows mammary epithelial cells to grow within a 
basement membrane derived from an Engelbreth-Holm-Swarm tumor and form acini, 
alveolar-like speres (G. Y. Lee, Kenny, Lee, & Bissell, 2007). The mammary epithelial 
cell line MCF10A form organized acini by day 12 with clear apical-basal polarity and a 
defined luminal space (Debnath, Muthuswamy, & Brugge, 2003). These cells will not form 
the same tight junctions found in primary human mammary epithelial cells (hMECs) 
(Underwood et al., 2006), because they lack Crumbs3 (Fogg, Liu, & Margolis, 2005), but 
are a very stable cell line that can be easily manipulated to study pathway regulation in 
developing acini. The MCF10A cells were used to derive the MCF10AT1 (AT1) line that 
has Ras activation and will form hyperplastic acinar structures. These lines are therefore a 
very useful model of early breast cancer progression in vitro (Choong et al., 2010; Dawson, 




Lee et al. (2005) were first to show that human cancer cells could successfully 
engraft and metastasize in zebrafish embryos. Melanoma cells were injected at the blastula 
stage of the embryos and survived up to 8 days post implantation (dpi) (L. M. Lee, Seftor, 
Bonde, Cornell, & Hendrix, 2005). It has since been observed that a cell’s metastatic 
behaviour is conserved in this xenotransplant model providing a fast and cost-effective way 
to model human metastasis in vivo. Zebrafish lack an adaptive immune system up until ~2 
weeks post fertilization allowing human cells to engraft without rejection; however, the 
innate immune system is active (at 2 days post fertilization (dpf)) which allows for the 
human cells to interact with a microenvironment similar to that of humans (Amatruda, 
Shepard, Stern, & Zon, 2002; Drabsch, He, Zhang, Snaar-Jagalska, & ten Dijke, 2013; 
Etchin, Kanki, & Look, 2011; Ghotra et al., 2012). Metastatic cell processes are strongly 
influenced by the microenvironment, so the zebrafish model is especially beneficial when 
studying metastatic processes in breast cancer. 
Spy1, a cyclin-like protein, can activate cyclin dependent kinases (CDK) 
independent of the canonical phosphorylation status (Cheng, Gerry, Kaldis, & Solomon, 
2005). Due to its unique conformation, the Spy1/CDK complex can uniquely 
phosphorylate CDK substrates and promote faster progression through the cell cycle. Spy1 
accelerates mammary tumourigenesis in mouse mammary transplants, and has elevated 
protein expression in breast cancer tumours, and promotes chemoresistance to Tamoxifen 
(Al Sorkhy et al., 2012; Ferraiuolo, Tubman, Sinha, Hamm, & Porter, 2017; Golipour et 
al., 2008; Lubanska et al., 2014). In brain cancer, Spy1 protein levels positively correlate 




been implicated in later stages of cancer, it has not been reported if Spy1 is involved in the 
processes that contribute to breast cancer metastasis. 
This study is the first to show a role for Spy1 in breast cancer metastasis. Breast 
cells, manipulated to overexpress Spy1, were able to invade and migrate in vitro and form 
distant metastases in an in vivo zebrafish model. Spy1 mediated invasion and migration are 
independent of EMT and β1-integrin activity was essential for invasion but not migration 
with Spy1-overexpressing cells. Protein expression analysis showed activation of the 
ERK1/2 pathway and this activation proved necessary for invasion and migration of breast 
cells. These findings are important advancements in the study of breast cancer progression 

















Materials and methods 
Animal Care 
Wildtype Zebrafish (Danio rerio) were maintained and cared for following Canadian 
Council for Animal Care guidelines, under the University of Windsor Animal Utilization 
Project Proposal # 12-14. Adult fish were kept at 28.5°C and bred according to protocols 
available in the Zebrafish Book (Westerfield, 1993). 
Cell Culture and Reagents 
MCF10A ATCC) and AT1 (Cell Lines Resource; Karmanos Cancer Institute, Detroit, 
MI).were grown in DMEM and Ham’s F-12 media (Sigma) containing 5% heat-inactivated 
Horse Serum (HyClone) supplemented with 5µg/mL insulin (Sigma), 0.5µg/mL 
hydrocortisone (Sigma), 10ng/mL epidermal growth factor (Sigma), and 0.1µg/mL cholera 
toxin (Sigma). MDA-MB-231 cells were cultured in Dulbecco's Modified Eagle Medium 
(DMEM) with 10% fetal bovine serum (FBS). All cell lines were maintained in media 
containing 2mmol/L L-glutamine (Sigma) and penicillin-streptomycin (Sigma) and were 
maintained at 37°C in a 5% CO2 environment. 
Lentiviral Infection 
Lentivirus production and infection was carried out following a modified protocol from the 
Welm group (Welm, Dijkgraaf, Bledau, Welm, & Werb, 2008). LentiXTM 293 producer 
cells (Cat. No. 632180, Clontech CA) were transfected with polyethylenimine, the 
supernatant was collected, filtered, and stored at -80C. MCF10A, AT1, and MDA-MB-231 
cells were seeded at 20,000 cells/well, 10,000 cells/well, and 10,000 cells/well 




with 6µl lentivirus/100ul media supplemented with 8µg/mL polybrene. All cells infected 
with pLKO empty control vector and pLKO-shSpy1 knockdown vectors were maintained 
in growth media containing 1ug/mL puromycin.  
RNA extraction and qRT PCR 
Total RNA was extracted using RNeasy Plus Mini Kit (QIAGEN) following the 
manufacturer’s protocol and reverse transcribed using 200U Superscript 11 (Invitrogen), 
0.5μg OligodT's and 0.5μg random nanomers (Sigma) according to manufacturer’s 
protocols. Quantitative real-time polymerase chain reaction (qRT-PCR), using either an 
ABI Prism 7300 or Viia7 thermocycler, with SYBR green (Applied Biosystems) 
fluorescent detection and 200-250nM of forward and reverse primers was performed. 
GAPDH was used as the endogenous control for all RT-PCR experiments. Data was 
analyzed using ABI Prism 7300 or Viia7 software and graphed as relative quantification 
(RQ) to control.  
Transwell Cell Migration and Invasion Assays 
Transwell cell migration assays were performed in 12 well cell culture plates using 8μm 
cell inserts (BD biosciences, catalog#:353093). 1ml of complete growth media was added 
to each well and the insert placed on top followed by incubation at 37°C for 1hr. 100,000 
cells suspended in 500µl serum free media were seeded into each insert and cells were 
allowed to migrate at 37°C for 24hrs. Cell inserts were removed and the interior of the 
insert was washed with a distilled water dampened Q-tip, and then stained with 400µl of 
crystal violet stain (Cell Biolabs, catalog#: CBA-100) for 10mins at room temperature. Cell 
inserts were gently washed with distilled water and allowed to dry for 10 mins. Pictures of 




measure the relative intensity of the staining on the membrane. For the transwell invasion 
assay the protocol is as above except that 100ul of Cultrex® (Trevigen #3433-010-01) 
diluted to 6mg/mL with serum free media, was added to each well and allowed to solidify 
at 37°C for 1hr before the cells were seeded in the well. For ERK1/2 inhibition, 10μM 
SCH772984 (ApexBio, A3805) was added to the cells before being seeded into the 
transwell chamber. MEK inhibitors, 10μM SB202474 (control; EMD Millipore, 559387) 
or 10μM U0126 (MEK 1/2; EMD Millipore, 662005), were added into the well of the insert 
with serum-free media. To block β1-integrin activity a β1-integrin antibody (Millipore: 
MAB1959) at 20ug/ml was incubated with the cells for 1 hr prior to adding cells to the 
insert. Human IgG antibody (Biorbyt Ltd.: ORB27741) at 20µg/ml was used as control.  
Zebrafish Xenotransplantation and Analysis 
Eggs were collected and kept at 28.5°C in an incubator in embryo media (E3) (5mM NaCl, 
0.17mM KCl, 0.33mM CaCl2, 0.33mM MgSO4, 10
-5% Methylene Blue) until ready to 
inject. Immediately before injections, 500,000 cells/500µL serum free media were labeled 
with 5µL of either DiO (green), or DiD (far red) (Vybrant, Invitrogen# V-22886). Forty-
eight hrs post fertilization (48hpf) embryos were dechorionated with fine tip forceps and 
anesthetized with 0.168mg/ml of tricaine (MS-222, Sigma). Approximately 50-100 
cells/9nL were resuspended in DMEM (Sigma) and 9nL of cell suspension were injected 
into the yolk sac of each embryo using Nanoject II (Fisher Scientific, cat # FSSP9706473)). 
After injection embryos were kept in E3 embryo media and imaged 2hpi with a 
fluorescence microscope (Leica M205 FA) to eliminate any fish with cells outside of the 
yolk sac. At 24, 48 and 72hpi the fish were imaged again using a fluorescence confocal 




Rate of invasion and migration was determined using a modified analysis protocol from 
Ghotra et al. (Ghotra, et al., 2012) with ImageJ. Each image was imported into ImageJ, 
aligned to the same orientation, and cropped so the injection sites (yolk sacs) would all 
have the same figure coordinates. The images were converted to a 32-bit greyscale and the 
threshold was adjusted to eliminate background pixels. The injection sites were chosen as 
the midpoint of the yolk sacs. Using the measure function the exact coordinates for the 
injection site were measured. The “Analyze Particles” tool was used to measure the 
coordinates and area of each tumour foci. All measured results were copied into Excel files 
for later analysis. Using Excel, the coordinates of each tumour foci were corrected to the 
injection site coordinates using the formula: (Xfoci-Xorigin,Yorigin-Yfoci). For each foci the 
distanced travelled from the injection site was calculated using the formula: 
√(Xcorrected
2+Ycorrected
2). The cumulative distance (CD) of all foci was calculated per embryo 
(Ʃfocin) and averaged within an experimental group to determine mean CD. A fish was 
determined to have metastasis if there were tumour foci outside of the yolk sac. Foci found 
outside the yolk sac were also counted to determine average metastases per fish.  
Immunoblotting 
Protein analysis was performed following a previously described protocol (Al Sorkhy, 
Fifield, Myers, & Porter, 2016). Briefly, 50µg of total protein was loaded on a 10% SDS-
PAGE gel and ran at 120V for 2.5-3hrs until separation of protein bands. Protein was 
transferred to nitrocellulose membranes at 30V for 2.5hrs. Membranes were blocked with 
5% BSA for 1hr then incubated with primary antibodies overnight at 4°C. Secondary was 
applied for 1hr at room temperature. Primary antibodies used were: Spy, Thermo Fisher: 




ERK 1/2 (Thr 202/Tyr 204), Cell Signaling:4370; E-cadherin (24E10), Cell signaling: 
3195 ; β-catenin, Cell Signaling:8480.  
Immunofluorescence (IF) and Confocal Microscopy 
A modified protocol from Dr. B. Sloane (Li, Mullins, Sloane, & Mattingly, 2008) was used 
where cells were seeded onto Cultrex® covered coverslips in a 30mm culture dish and 
allowed to form acini. Coverslips were collected at 4 days and 12 days, washed with 37°C 
phosphate buffered saline (PBS) and fixed in either -20°C Methanol for 10mins or room 
temperature 4% paraformaldehyde in PBS for 20mins depending on antibody 
specifications. Fixations were quenched with 0.75% Glycine in PBS for 10mins. Cells were 
permeabilized with 0.5% Triton X-100 in PBS for 10mins and blocked with a 1hr 
incubation in IF buffer: 130mM NaCl, 7mM Na2HPO4, 3.5mM NaH2PO4, 0.1% bovine 
serum albumin (BSA), 0.2% Triton X-100, and 0.05% Tween-20, pH 7.5. Cells were 
incubated with primary antibody in IF buffer at 4°C overnight in a humidity chamber 
followed by three IF buffer washes of 10mins. Cells were incubated in secondary antibody 
in IF buffer for 1hr at room temperature in a darkened humidity camber. After three IF 
buffer washes of 10mins, cells were incubated with TOPRO3 in PBS for 10mins followed 
by a PBS wash for 10mins. Coverslips were air dried for 30mins and then fixed onto slides 
with Prolong Gold Antifade reagent (Thermo Fisher P36930). Slides were imaged at 60x 
with a fluorescence confocal microscope (Olympus Fluoview). Acini size and protein 








Spy1 expression regulates mammary acini morphogenesis in vitro 
To determine if Spy1 could induce early indicators of tumourigenic events in mammary 
cell lines in vitro, we used the MCF10A mammary cell line and the H-Ras transformed 
derivative, AT1. MCF10A cells form highly organized single-acinar structures when 
cultured in ECM and are frequently used to model mammary alveolar morphogenesis in 
vitro. Spy1 overexpression in the MCF10A cells caused larger acinar structures, as 
compared to control cells, after 4 and 12 days in culture (Figure 5.1 A). The acini developed 
into more multiacinar as opposed to single acinar structures (Figure 5.1 A). 
The transformed AT1 cells on the other hand, are known to form hyperplastic acini 
in vitro but have low invasive potential. The AT1 line expresses Spy1 protein at higher 
levels than the MCF10As but lower levels than the MDA-MB-231s (Al Sorkhy, et al., 
2012) so we wanted to determine if overexpressing Spy1 in the cells could increase their 
disorganization in 3D culture and perhaps show a more invasive phenotype. When Spy1 
was exogenously overexpressed in the AT1 cells, they formed larger acini than control 
cells after 4 and 12 days (Figure 5.1 B). There was no change in the frequency of 
multiacinar structures with approximately 71% and 78% being multiacinar in control and 
Spy1 cells, respectively (Figure 5.1 B).  
We used shRNA-mediated knockdown in the AT1 cells (termed shSpy1 cells) to 
determine if reducing Spy1 expression could revert these structures from a hyperplastic 
morphology to a normal morphology. The acini formed with shSpy1 cells were smaller 




in percentage of multiacinar structures from approximately 82% in control cells to 52% in 








Figure 5.1. Aberrant Spy1 causes abnormal mammary acini formation.   
Representative images of MCF10A (A), AT1 Spy1 overexpression (B), and AT1 cells with 
Spy1 knockdown, that have been infected with control, Spy1 overexpression or shRNA 
Spy1 knockdown lentivirual vectors and grown in growth-factor reduced Cultrex® for 4 
and 12 days. Graph represent quantification of acinar size at 4 and 12 days and % of multi 
or single-acinar structures formed. Statistical anaysis performed using Students t-test, * 
p<0.05, ***p<0.001. Error bars represent mean ± SEM, n= at least 140 acini counted over 



















Elevated Spy1 levels promote cell growth and disrupt acini organization   
Acini were fixed for immunofluorescence assays to determine if the multi-acinar structures 
formed in the presence of elevated Spy1 levels were caused by over proliferation (Ki67 
expression levels), disruptions in cell-cell polarity (β-catenin and E-cadherin localization), 
disruptions in apical-basal polarity (GM130 localization), or alterations in cell-EMC 
interactions (Laminin V localization). These are all events that take place in early 
tumourigenic and metastatic processes (Debnath, et al., 2003; Yoshida, Kimura, Harada, 
& Ohuchi, 2001). The loss of β-catenin and E-cadherin expression at the cell junctions is 
one of the hallmarks of cells undergoing EMT and seen in many metastatic cells (Onder et 
al., 2008; Yoshida, et al., 2001). Cross-sections of MCF10A cells were obtained by 
confocal microscopy after 4 and 12 days of growth in 3D culture. Overexpressing Spy1 in 
these cells did not change in E-cadherin, β-catenin, or Laminin V localization (Figure 5.2 
and Figure S5.1 A-C) as compared to control cells. They did have an increase in Ki67 
expression, and GM130 mis-localization after 4 days in culture (Figure 5.2 A and C). This 
supports that the acini were more proliferative and more disorganized than control acini. 
Day 12 acini had no change in Ki67 expression with Spy1 overexpressing cells but had 
more cells with mislocalized GM130 (Figure 5.2 B-C). Protein levels in MCF10A and 
MDA-MB-231 cells confirmed that E-cadherin and β-catenin protein levels were 
unchanged with manipulation of Spy1 expression (Figure S5.1 C) and SPDYA gene 
expression was confirmed using qRT-PCR (Figure S5.1).  
AT1 acini with Spy1 overexpression were also stained for β-catenin, Ki67, and 
GM130 (Figure S5.2). Again, there was no change in β-catenin localization at day 4 but 




showed no change in Laminin V or β-catenin localization (Figure S5.3,Figure 5.3) but there 
was a decrease in Ki67 expression and an increase in the number of acini with hollow 


























Figure 5.2. MCF10A cells overexpressing Spy1 form hyperplastic, disorganized acini. 
MCF10A control and Spy1 overexpression cultures were collected at Day 4 (A) and Day 




(C) Graphs represent quantification for % of cells with GM130 mislocalized, % of cells 
expressing Ki67. Data represents mean ± SEM, n=at least 130 cells counted over 3 

























Figure S5.1. MCF10A cells overexpressing Spy1 do not change cell-cell protein 
expression.  
(A) MCF10A control and Spy1 overexpression cultures were collected at Day 4 and stained 
with antibodies specific for laminin V. (B) Graph represents quantification for % of cells 
localizing β-catenin. (C) % of cells localizing E-cadherin. n=at least 130 cells counted over 
3 independent experiments. (D) protein expression of E-cadherin and β-cateinin in 




WT, control (pLKO), or shSpy1 expression. One representative blot of n=3. (E) graphs 
representing relative quantitation (RQ) SPDYA/GAPDH mRNA expression in MCF10A 
and MDA-MB-231 cells. n=3. Data represents mean ± SEM, statistical anaysis performed 
























Figure S5.2. Transformed AT1 cells overexpressing Spy1 are hyperproliferative but do not 
exhibit EMT properties.  
(A) AT1 control and Spy1 overexpression cultures were collected at Day 4 and stained 
with antibodies specific for b-catenin, Ki67, and GM130. (B) Graphs represent 




Day 12 acini were stained with β-catenin. Data represents mean ± SEM, n= at least 130 


























Figure 5.3. Depleting Spy1 reverts hyperplastic acini back to a more normal phenotype. 
(A) AT1 control and shSpy1 expressing cultures were collected after 4 days and stained 
with antibodies specific for b-catenin, Ki67, and GM130. Graphs represent quantification 
for % of cells expressing Ki67, % of acini with hollow lumen, and % cells with GM130 
mislocalization. (B) AT1 control and shSpy1 expressing cultures were collected after 12 




the % of acini with hollow lumen. Data represent mean SEM, statistical anaysis performed 











Figure S5.3. AT1 cells with Spy1 knockdown have no change in Laminin V or β-catenin 
expresssion.  
(A) AT1 control and shSpy1 acini were collected at Day 4 Laminin V. (B) Graph represents 
quantification for % of cells localizing β-catenin. Data represents mean ± SEM, statistical 








Spy1 enhances the metastatic behaviour of mammary epithelial cells 
Breast cancer cell metastasis is a multi-step process that is often initiated in the alveolar 
structures of the mammary gland (Muschler & Streuli, 2010; Shousha, Backhous, 
Alaghband-Zadeh, & Burn, 1986). The initial processes include the increased proliferation 
and disorganization of alveolar cells, followed by invasion and migration of the cells 
through the ECM most often thought to occur with cells undergoing EMT. Based on the IF 
staining in Figure 5.2-Figure S5.3, manipulating Spy1 expression did not alter the 
expression of proteins classically involved in EMT in mammary cells, however there was 
disruption in the organization of the acini. We then used functional assays for migration 
and invasion to determine if altering Spy1 protein levels resulted in a change in these 
classical in vitro assays.   
MCF10A cells were infected with either a control vector or a vector stably 
expressing Spy1 and Boyden transwell migration and invasion assays were performed. 
After 24 hrs, overexpression of Spy1 caused a significant increase in cell migration and 
invasion (Figure 5.4 A). Since the invasive cells line MDA-MB-231 cells have increased 
Spy1 expression compared to normal mammary cells (Al Sorkhy, et al., 2012), we knocked 
down Spy1 using shRNA and found that invasion and migration through transwell 






Figure 5.4. Spy enhances metastatic behaviour of mammary cells.   
(A) MCF10A cells with Spy1 overexpression and (B) MDA-MB-231 cells with Spy1 
knockdown after 24hrs transwell migration assay. Micrographs taken with 10x objective. 
Scale bar=100µm. Graph represents relative migration of Spy1 or shSpy1 compared to 






Spy1 promotes breast cancer metastasis in vivo  
To determine if elevating Spy1 levels would have the same effect on cell invasion and 
migration in vivo, a zebrafish xenograft model was used. The optimal cell dilution and time 
post injection was determined by injecting different quantities of cells and quantifying 
every 24hpi. The optimal number of injected cells was more than 30 and cell metastasis 
was highest 72hpi (Figure S5.4). 72 hrs after injection, the MCF10A cells overexpressing 
Spy1 had travelled further than the cells expressing the control vector (Figure 5.5 A-B). In 
addition, a higher percentage of fish with Spy1 overexpression cells had metastasis as 
opposed to control cells and there were significantly more metastases per fish with Spy1 
overexpression (Figure 5.5 C). Depleting Spy1 expression in the MDA-MB-231 cells did 
not change the cumulative distance travelled by the cells or the percentage of fish with 
metastasis, however there was a decrease in the number of metastases per fish with 
knockdown (Figure 5.5 D-F). Spy1 depletion in AT1 cells caused a significant decrease in 













Figure S5.4. Cell dilution to determine optimal number of cells for zebrafish xenograft. 
Graphs represent (A) total Raw Integrated Density of xenographs. Each point represents 1 






Figure 5.5. Spy1 regulates breast cancer metastasis in vivo.   
(A) Representative fluorescence stereomicroscopy images 72 hours after injection of 
MCF10A cells expressing Control (red) and Spy1 (green) overexpression vectors. (B) 
Quantification of the cumulative distance travelled by cells 72 hours post injection. Each 
point represents one injected fish. (C) Graphs representing the % of fish that had metastasis 




separate infections. (D) Representative fluorescence stereomicroscopy images 72 hours 
after injection of MDA-MB-231 cells with Control (green) and shSpy1 (red). (E) 
Quantification of the cumulative distance travelled by cells 72 hours post injection. Each 
point represents one injected fish. (F) Graphs representing the % of fish that had metastasis 
outside of the yolk sac 72 hours after injection and metastases/fish. n=29 fish from 2 






















Figure S5.5. Knockdown of spy1 decreases invasion and migration in vivo.  
(A) 24 hpi of AT1 cells infected with control or shSpy1 vector. Graphs represent 
coordinates of each tumour foci for all control or Spy1 injected fish with 0,0 being the 
injection site. (B) Graph representing the CD of control and Spy1 injected fish.  Each point 
represents the CD of one fish. n=51 (C) graph representing relative quantitation (RQ) 





Spy1 increases β1-integrin and ERK1/2 expression 
While Spy1 functionally increased invasion and migration (Figure 5.4), markers of EMT 
were unchanged (Figure S5.1 and Figure S5.3). This led us to investigate alternate 
pathways that would explain how Spy1 is regulating migration or invasion while 
maintaining E-cadherin expression. Two very important interactions for metastatic 
regulation are cell-cell and cell-ECM (Lock, Wehrle-Haller, & Stromblad, 2008). Because 
Spy1 was not visibly affecting cell-cell adhesion, we further investigated Spy1 regulation 
of cell-ECM interactions.  
 Increased Spy1 protein expression led to an increase in β1-integrin expression 
(Figure 5.6 A), one the main modulators of cell-ECM interactions (Lambert, Ozturk, & 
Thiagalingam, 2012; Lock, et al., 2008). Because β1-integrin regulation is through 
activation of the integrin subunit binding to ECM, we used a β1-integrin antibody to block 
activation of the integrin subunit and inhibit downstream signaling. Interestingly, blocking 
β1-integrin activity did not affect migration but reduced invasion of MCF10A cells through 
the transwell chamber (Figure 5.6 B).  
One of the main downstream signaling pathways activated by β1-integrin binding 
to ECM is focal adhesion kinase/ERK1/2 signaling which has been shown to upregulate 
metastasis in breast cancer cells (Jiang, Pan, Cheng, Li, & Liu, 2016; Provenzano, Inman, 
Eliceiri, & Keely, 2009). Previous work has shown that Spy1 is able to activate ERK1/2 in 
breast cancer cells but this has never been explored in normal breast cells (Ferraiuolo, et 
al., 2017). Protein expression revealed that exogenous expression of Spy1 caused an 





Small molecule inhibitors for ERK1/2 and MEK were used to determine if this 
pathway is involved in Spy1 mediated invasion and migration. Migration through 
transwells was significantly decreased with the ERK1/2 inhibitor and although decreased 
with the MEK inhibitor, it was not statistically significant (Figure 5.7 A). Invasion was 




















Figure 5.6. Spy1 increases β1-integrin and requires its activity for invasion.  
(A) western blot of whole cell lysates from 10A cells overexpressing Spy1 were probed 
with the antibodies indicated on the left side of each panel. Graphs represent densitometry 
analysis of antibodies indicated on Y-axis. MCF10A cells expressing control and Spy1 
overexpression vectors were seeded into transwell chambers for (B) migration and (C) 
invasion. Graphs represent relative intensity measured using ImageJ. Data represents mean 






Figure 5.7. Spy1 requires ERK1/2 activation for invasion and migration.   
Boyden (A) migration and (B) invasion assay with control and ERK inhibitors and control 
(SBB) and MEK (U0126) inhibitors in MCF10A cells expressing control or Spy1 
overexpression vectors. Graphs represent relative intensity measures using ImageJ. Data 













Breast cancer has become a highly treatable disease but is still the second leading cause of 
cancer deaths in women (Bray, et al., 2018) worldwide. Once breast cancer metastasizes to 
distal organs it becomes very difficult to treat and is most often fatal. Understanding the 
mechanisms of metastasis may improve treatments for patients who have metastatic disease 
and/or they may prevent earlier stage disease from progressing. In this study we show a 
novel role for Spy1, a cell-cycle regulator, in mediating processes required for breast cancer 
metastasis.  
 Disorganization and hyperplasia in mammary alveoli are early processes in breast 
cancer metastasis and disruption in the cell-matrix interactions can lead to breast cancer 
(Bussard & Smith, 2012; Muschler & Streuli, 2010). In our study, Spy1 significantly 
increased disorganization in a 3D cell culture mammary acini model with a loss of apical-
basal polarity and significantly more proliferation in early acini development. However, 
the cells were able to maintain the cell-cell interactions with no change in β-catenin or E-
cadherin expression or localization. When cells were implanted into a zebrafish embryo 
metastasis model, Spy1 was able to increase the formation of metastases in MCF10A cells.  
 Recent studies, in both breast and pancreatic cells, have shown that EMT may not 
be a necessary process for cell metastasis (Fischer, et al., 2015; Zheng, et al., 2015). In our 
study, breast cells overexpressing Spy1 are able to invade, migrate, and metastasize but 
they do not go through classical EMT. The cells do not lose E-cadherin expression and do 
not change to mesenchymal morphology. A possible mechanism of Spy1 mediated 




dissemination that has been previously described (Christiansen & Rajasekaran, 2006; Clark 
& Vignjevic, 2015; Jolly, Ware, Gilja, Somarelli, & Levine, 2017). 
 Protein expression analysis revealed exogenous expression of Spy1 protein can 
increase β1-integrin expression and activate ERK1/2 signaling which, in turn, was shown 
to be involved in Spy1 mediated invasion and migration as seen by the use of small 
molecule inhibitors for ERK1/2. β1-integrin activity was necessary for invasion but not 
migration in Spy1 overexpressing cells, as seen by blocking antibodies experiments. It is 
possible that integrin signaling is needed to increase matrix metalloproteinase (MMP) 
expression and function to degrade the ECM and facilitate cell invasion but maybe this 
signaling is not needed to migrate when no ECM is present. In breast cancer cells the 
fibronectin- α5β1-integrin interaction can induce MMP-2 and MMP-9 expression and 
activation (Chao, Shepard, & Wells, 2010). This study did not determine which, if any, α 
integrin subunits are also necessary for Spy1 mediated metastatic processes and this would 
be a valuable future direction.  
 Because of the incurable nature of metastatic breast cancer, it is imperative to 
determine the cellular processes that lead to cell metastasis and find better treatment 
programs for the patients that have this fatal disease. We were able to show, for the first 
time that Spy1 is a crucial regulator of cell invasion processes and that this regulation is 
independent of EMT but requires β-integrin and ERK1/2 signaling.    
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Zebrafish as a model system for cancer processes and cancer drug toxicity   
One of the main objectives of this work was to set up and optimize a zebrafish model as a 
multi-faceted system to study human cancer processes as well as drug toxicity. This 
included starting a colony, optimizing feeding and breeding protocols to obtain maximum 
egg production for high throughput experiments, and optimizing many different assays, 
that had previously never been utilized by our research group, to study different cancer 
processes.  
As shown in this work, we successfully validated the use of this zebrafish model 
for many different cellular processes. This included the study of the effects of anti-
inflammatories on cell metastasis, the toxicity of breast cancer drug combinations, the 
effectiveness of a natural health product (NHP) in reducing inflammatory processes, the 
role of a cell cycle regulator on mammary cell metastasis, and in a previously published 
study, drug resistance of breast cancer cells to tamoxifen (Ferraiuolo, Tubman, Sinha, 
Hamm, & Porter, 2017). These diverse applications highlight the versatility of this model. 
Being able to use the same animal model for multiple avenues of research is a huge 
advantage, reducing research costs and research time that would otherwise be spent 
optimizing multiple animal models.  
Zebrafish were first proposed for use in research in 1934 (Creaser, 1934) and  were 
the first fish species to be involved in carcinogenesis research (Spitsbergen & Kent, 2003) 
so using fish to study cancer is not a new concept. However, it wasn’t until into the 1990’s 
and early 2000s when the genome of the zebrafish was sequenced that this model system 
began to be appreciated as an accurate model for human diseases (Spitsbergen & Kent, 




genes have homologs in the zebrafish (Howe et al., 2013; Kettleborough et al., 2013; 
Santoriello & Zon, 2012), which further supports the use of this model in mimicking human 
diseases.  
Our aim was to validate the use of zebrafish to study human cancer processes to be 
a complimentary system to the mouse models available in our research facility. Mouse 
models are an invaluable tool for cancer research as they closely mimic humans genetically 
(Waterston et al., 2002). The main disadvantage with the mouse model is the cost of 
housing and the labour required to maintain a large mouse colony, especially if that 
involves creating/maintaining transgenic and knockout/in strains. Zebrafish are a relatively 
inexpensive animal model with very low maintenance cost once the aquatic system is set 
up. Each healthy female can produce ~200-300 eggs per week which allows for easy 
maintenance of stocks.  
There are also advantages in the ease of imaging zebrafish over mice. In mice, live 
imaging of tumour cells requires a very expensive in vivo fluorescence/bioluminescence 
imager that is not readily available to many researchers. However in zebrafish, the embryos 
can be imaged, alive, with any light microscope (or fluorescent scope if labelled cells are 
used) because the embryos remain mostly transparent until 3-6 weeks post fertilization 
(Eskova et al., 2017). Furthermore, there are pigmentation mutants available such as the 
roy-/-;nacre-/- (casper) or nacrew2/w2;albb4/b4;roya9/a9 (crystal) mutants that are completely 
transparent throughout development. These points enable the live embryo to be monitored 
for a long period of time, supporting the study of development and/or organ toxicity. 
Transparent genetic strains are more difficult to maintain and hence have not yet been 




been optimized, the casper or crystal fish would be a great addition to continue with 
metastatic studies as tumour foci could be visualized for a longer period. 
One of the main advantages of the zebrafish in cancer studies is the fact that the 
immune system develops in stages so human cells can be injected in the first 1-2 weeks of 
development because the adaptive immune system is not yet mature and human cells can 
engraft without host rejection. The innate immune system is active at this stage and 
therefore the embryos are immunocompetent which allows for an intact microenvironment 
for more accurate study of cancer process that rely on environmental signals; migration 
and invasion, for example (Antinucci & Hindges, 2016; Tang et al., 2016; White et al., 
2008). If human cells are to be engrafted into mice, an immunodeficient model is needed 
which is very costly and less biologically relevant because the immune system cannot 
influence the engrafted cells in the way that it would in human cancers (Ito, Takahashi, 
Katano, & Ito, 2012; Somasundaram et al., 1995). The largest disadvantage for the 
zebrafish model for the study of breast cancer processes is the fact that zebrafish do not 
possess breasts and there is no structure homologous to the breast outside of mammal 
models. However, the model has many aspects which accurately mimic cancer processes 
as they occur in human beings, such as tumour proliferation, invasion, migration, and 
angiogenesis. Monitoring invasion and metastasis in patient-derived cells that have been 
transplanted into the fish (also referred to as xenotransplantation), can be efficiently 
conducted in the yolk because the yolk is separated from the embryo by a syncytial layer 
(Kimmel & Law, 1985), thereby requiring cancer cells to actively invade from the yolk 
into the developing organism to metastasize. This mimics the process by which cells escape 




each separated from the other with stromal tissue (Cardiff & Wellings, 1999). In human 
breast cancer, the most common metastatic site is to the bone, followed by the lung, brain, 
and liver (Patanaphan, Salazar, & Risco, 1988) and in our lab, as well as others, tumour 
foci most often set up in the tail bones of the embryo once the cells have invaded through 
the yolk (Ren, Liu, Cui, & Ten Dijke, 2017; X. X. Wu et al., 2018). Another important 
process in breast and other cancers, is tumour angiogenesis. We were able to model this 
process in the zebrafish using alkaline phosphatase staining, which is a method that has 
been previously used in zebrafish angiogenesis (Moshal, Ferri-Lagneau, Haider, 
Pardhanani, & Leung, 2011). Hence, although we are not able to examine gross mammary 
gland development in the zebrafish model, we are able to model the processes that are 
important for tumourigenesis and metastasis.  
These assays are currently being used in by our researchers to model other human 
cancers, such as glioblastoma and prostate cancer and will continue to be an important 
asset. To date we have only used a wildtype strain of zebrafish but in the future, we will be 
developing casper strains to permit long term, specialized studies. 
The use of anti-inflammatories in combination with breast cancer treatments 
The anti-inflammatory properties of dexamethasone (Dex) make it an attractive antiemetic 
to combat the side effects of chemotherapeutics. However, concern was raised about the 
protective effects of Dex on breast cancer cells almost 20 years ago by the Conzen lab 
(Mikosz, Brickley, Sharkey, Moran, & Conzen, 2001; Moran, Gray, Mikosz, & Conzen, 
2000; W. Wu, Pew, Zou, Pang, & Conzen, 2005). Our lab has also previously shown that 
in breast cancer cell lines, Dex has an antagonistic effect on cell death when used with the 




NFκB (Crozier & Porter, 2015). To further dissect the effect of Dex on other cancer cell 
processes, this work tested the effects of Dex treatment on cell migration and invasion in 
vitro and cell metastasis in vivo.    
Our in vitro data showed that Dex positively regulated cell metastasis in triple 
negative breast cancer (TNBC) cell lines but not in ER+ cell lines. When we 
xenotransplanted the TNBC cells, MDA-MB-231, and ER+ cells, MCF7, and treated the 
embryos with 10 or 100µM of Dex we saw that both cell lines had a significant increase in 
the frequency of fish with metastasis and the total distanced travelled away from the 
injection site as compared to DMSO treated embryos. This difference between Dex effects 
on MCF7 cells in vitro and in vivo could be due to both cell lines being injected together 
into the same fish causing some interaction between the two cell lines to promote 
metastasis of the MCF7 cells with Dex treatment. MDA-MB-231 cells have been shown 
to secrete factors that recruit immune cells to promote metastasis (Erler et al., 2009) and it 
is known that zebrafish immune cells, specifically neutrophils, can interact and promote 
metastasis of human tumour xenografts (S. He et al., 2012). It would be interesting to 
determine if this is the case with the co-injected cells by injecting MCF7 cells alone into 
the zebrafish to see if cells are still able to metastasize after Dex treatment. This study 
presents further evidence that in vitro assays are not sufficient for determining invasive 
ability of cells but should be complemented by in vivo studies. 
Gene analysis of cells treated with Dex in vitro show a significant increase in 
WNT5A expression in MDA-MB-231 cells but not in MCF7 cells. WNT5A is a non-
canonical Wnt ligand that is involved in planar cell polarity and epithelial-mesenchymal 




whether WNT5A is able to promote tumourigenesis or act as a tumour suppressor as 
detailed in a review by Zeng et al. (2016). A recent study with Dex-treated cells reported 
that Dex enhanced metastasis through WNT5A and its receptor ROR1 (Obradovic et al., 
2019). In that study, WNT5A expression was elevated in metastases from mice treated with 
Dex and downregulating ROR1 expression decreased Dex-induced metastasis (Obradovic, 
et al., 2019). They did not examine MCF7 or any other ER+ cells lines but our work 
suggests that WNT5A is not affected by Dex in the ER+ MCF7 cells and it is not regulating 
migration. A valuable assay for us to dissect the role of WNT5A in Dex mediated 
metastasis is to either treat cells with WNT5A inhibitors before xenotransplantation into 
the zebrafish or treat the zebrafish media with inhibitors to determine if metastasis is 
ablated. It is possible that in the zebrafish microenvironment WNT5A is activated in the 
MCF7 cells and that could be determined by collected cells post-transplant and looking at 
gene expression. A large number of embryos would have to be pooled together to get 
sufficient human mRNA as so few cells are transplanted into the embryos.  
It has been previously shown that IL-6 can upregulate transcription of WNT5A, 
through STAT-3 signaling, and this can induce cell migration through the non-canonical 
RHO/RAC Wnt pathway specifically during chronic inflammation and carcinogenesis 
(Katoh, 2007). Also, that glucocorticoids have been implicated in inducing the expression 
of the purinergic receptor, P2Y2R, which increases IL-6 secretion (Ding, Gao, Jacobson, 
& Suffredini, 2010). It would be valuable to look at activation and expression of STAT-3 
and P2Y2R after Dex treatment in our system to confirm that this is the active pathway 




Expression of il6 in the zebrafish embryos after Dex treatment was unchanged, 
however il1β and tnfα were elevated after prolonged Dex treatment, perhaps through the 
same P2Y2R mechanism as mentioned above (Ding, et al., 2010). Previously, the 
glucocorticoid beclomethasone was noted to reduce il1β expression in zebrafish embryos 
but treatment was only continued up to 25hrs so long term treatment was not examined 
(Chatzopoulou et al., 2016). We did not collect fish after short-term exposure, at these 
lower concentrations, so there may be an initial suppression of the immune response 
followed by compensatory activation with longer exposure times.   
The interaction of Dex with cancer cells is not the only concern when Dex is given 
to breast cancer patients. The chemotherapeutics that are given with Dex have many 
reported side effects but little has been reported as to whether Dex directly affects the 
severity of the observed side effects, aside from the consensus that Dex is effective in 
reducing nausea and appetite loss (Chu et al., 2014). In embryos treated with Dex and 
common treatments for breast cancer, cyclophosphamide and paclitaxel, we saw that Dex 
enhances cardiotoxicity and hepatotoxicity in zebrafish embryos and larvae with 
cyclophosphamide but does not have these toxic effects with paclitaxel. For measuring 
hepatotoxicity we used previously described assays (J. H. He et al., 2013; Vliegenthart, 
Tucker, Del Pozo, & Dear, 2014) that measure liver size, opacity, and yolk retention. In 
the Dex and cyclophosphamide treatment group the liver was very hard to distinguish 
because of the amount of fluid buildup in the pericardial sac. It would be beneficial to use 
a probe or stain that would aid in visualizing the liver. Aside from transgenic fish that have 
liver specific reporters, there is the previously described glucose bioprobe conjugated to 




probe to measure glucose metabolism and function in the liver based on the principle that 
a healthy liver will uptake the GB2-Cy3 probe and we can compare the amount of 
fluorescence in the control and treated embryos (Seth, Stemple, & Barroso, 2013).    
Gene analysis after treatment showed an upregulation of mmp9 expression with the 
combination of Dex and cyclophosphamide which may contribute to the observed increase 
in edema as Mmp9 activation has previously been associated with edema in zebrafish 
(Zhang, Huang, Wang, Gao, & Zuo, 2013). We attempted to use ERK inhibitors to block 
edema formation as there is evidence that ERK regulates MMP-9 expression in human 
brain edema (Arai, Lee, & Lo, 2003; Mori, Wang, Aoki, & Lo, 2002), however, Erk 
signaling is extremely important in the developing embryo especially for response to 
environmental stressors (Keller, Escara-Wilke, & Keller, 2008) and in our preliminary 
studies, the ERK inhibitor accentuated the edema caused by the drug treatments so a more 
direct method to block Mmp9 activation in zebrafish is being optimized for future studies.  
One caveat to the study of cyclophosphamide in zebrafish is that a very high 
concentration is needed to get an internal concentration in the fish that is relevant to what 
breast cancer patients received. This is partly due to the nonionic nature of the drug and 
this makes it poorly absorbed by the embryo (Brox, Seiwert, Kuster, & Reemtsma, 2016). 
We are in the process of measuring drug absorption in the fish by HPLC and will follow 
up to determine what concentration of each drug is absorbed and metabolized by the fish 
in the single and combination treatments.            
 This work has shown that there is a clear need to continue studying the mechanisms 
of Dex to be able to assess its true value as an antiemetic for breast cancer patients. If the 




chemotherapeutics, there needs to be more effort to identify alternative anti-
inflammatories.      
Due to serious side effects seen in Dex we wanted to determine if there were natural 
health products (NHPs) that could be used to reduce inflammation and oxidative stress, 
two processes that are prevalent in cancer, without contributing to serious organ toxicity 
(Liguori et al., 2018; Willcox, Ash, & Catignani, 2004; Young & Woodside, 2001). Using 
zebrafish assays, we found that Nutria plus with SelenoExcell, an NHP, was able to reduce 
cell death due to UV exposure, increase rate of tissue repair after tail amputation, and 
prevent angiogenesis of engrafted tumour cells. The Nutria plus with high SelenoExcell 
concentration (HSe) formula is currently registered with Health Canada as an NHP. These 
preliminary results are a good foundation to continue investigating Nutria plus HSe as an 
anti-inflammatory and antioxidant however there is still a lot that can be done to ensure 
that this NHP is safe to administer in combination with chemotherapies. Future studies will 
include repeating the zebrafish toxicity assays with Nutri plus in the place of Dex to 
determine if there is a reduction in heart and liver toxicities. We also need to dissect the 
pathway regulation of Nutria plus HSe to ensure that inflammatory pathways are not being 
activated with this NHP as they are with Dex.  
The immune system is extremely important for normal development and has been 
implicated in providing protection against malignancy in the breast (Strayer, Carter, & 
Brodsky, 1986). However, in the context of cancer treatments, the immune system is 
responsible for many of the unwanted side effects of chemotherapeutics, such as 
inflammation and tissue damage (Chu, et al., 2014). Immune suppression is not only 




other diseases and conditions that cause sustained immune response. For example, immune 
suppressant drugs have been implicated in the onset of hepatosplenic T cell lymphoma, a 
rare form of aggressive cancer often seen in Chrohn’s and Lupus patients, transplant 
recipients, and other immune disorders (Belhadj et al., 2003; Carvao, Magno Pereira, 
Jacinto, Sousa Andrade, & Jasmins, 2019; Subramaniam et al., 2014). Future research will 
be directed at finding effective anti-inflammatories that are safer for long-term use.  
Spy1 Promotes Cell Metastasis via β1-integrin-ERK1/2 Pathway 
This work is the first to implicate the cell cycle protein, Spy1, in regulating mammary cell 
migration and invasion, both in vitro and in vivo. Exogenous expression of Spy1 in 
MCF10A cells increased acini disorganization in a 3D in vitro assay. Immunofluorescence 
of whole acini structures revealed that the cells overexpressing Spy1 lost their apical-basal 
polarity but maintained cell-cell contacts with a mislocalization of GM130 expression but 
no change in E-cadherin or β-catenin expression. There was an increase in proliferation 
rates in the early developing acini structures (day 4) but not late in development (day12). 
Laminin V expression was also unchanged which implies that the cell-matrix interaction is 
still intact even though the cells are not polarized properly. Inversely, when Spy1 
expression was downregulated in the transformed MCF10AT1 (AT1) cell line, the acini 
structures were smaller and more organized. Alveolar hyperplasia and disorganization are 
two processes in early breast cancer tumourigenesis before the cancer cells have breached 
the basement membrane (Donaldson et al., 2018; Lerwill, 2004). These effects led us to 
examine if Spy1 regulated late processes of tumourigenesis such as invasion, migration, 
and colonization. Using transwell assays, we determined that aberrant expression of Spy1 




model, we were able to show that Spy1 expressing cells had more invasion outside of the 
yolk sac and colonization of the tail. Cell invasion, migration, and tail colonization was 
attenuated with Spy1 knockdown in AT1 cells and metastases per fish was reduced in 
MDA-MB-231 cells.    
Even though Spy1 does not exhibit the classical markers of EMT (loss of E-
cadherin at the cell membrane, β-catenin translocation to the nucleus), it does regulate 
invasion and migration. Cell-ECM interactions are important for metastatic progression, 
so we looked at integrin expression in MCF10A cell lysates with Spy1 overexpression. 
Protein analysis revealed that Spy1 overexpressing cells had an increase in β1-integrin 
protein and blocking antibodies were able to inhibit Spy1 mediated invasion but not 
migration. The migration transwell assay does not contain any ECM components so it is 
possible that β1-integrin is not activated in these cells even though they do have increased 
protein expression.  
Previously, it was shown in multiple myeloma that when cells adhere to fibronectin, 
a β1-integrin ligand, Spy1 expression is actually downregulated which seems contrary to 
our results (Fei, Hang, Hou, & Ruan, 2013) but preliminary data from others in our lab 
show that Spy1 increases adhesion to collagen and plastic but not to fibronectin (Malysa, 
2011). Cell-ECM adhesion assays were not performed in this work but it would be 
beneficial to determine the adhesion properties of MCF10As overexpressing Spy1. 
The activation of β1-integrin has been shown to be dependent on talin binding to 
the cytoplasmic tail of the integrin (Chinthalapudi, Rangarajan, & Izard, 2018). It was 
recently shown that ras associated protein 1 (RAP1), a small guanosine triphosphate 




integrins and activating them (Bromberger, Zhu, Klapproth, Qin, & Moser, 2019). 
Regulators of RAP1 include extracellular agents such cyclic adenosine monophosphate and 
calcium (Bos, de Rooij, & Reedquist, 2001). A next step to further dissect how Spy1 is 
activating β-integrin would be to investigate RAP1 activation.  
RAP1, the β-integrin activator, is also involved in cell-cell adhesion processes 
through regulation of E-cadherin at the cell junction as seen in ovarian carcinoma cells 
where RAP1 inhibition led to a loss of E-cadherin from the cell surface (Price et al., 2004). 
This is interesting because we see no change in E-cadherin expression at the cell junctions 
when Spy1 is exogenously expressed yet we get invasion and migration of the cells.  It 
supports that Spy1-mediated effects do not require classical epitheial-mesenchymal 
transition (EMT) signaling. There is a growing body of work to support that EMT is not 
the only mechanism by which cells are able to metastasize, transitioning to ameboid 
migration for example (Radisky & Radisky, 2007), and that EMT is better described as a 
reversable process in which cells can exhibit a spectrum of epithelial or mesenchymal 
properties (Fischer et al., 2015; Jolly, Ware, Gilja, Somarelli, & Levine, 2017; Zheng et 
al., 2015).  
β1-integrin signals downstream through many different pathways. One of these is 
through phosphorylated ERK1/2. It is known that Spy1 can activate the MAPK/ERK1/2 
pathway through a proposed feedback loop with ER in breast cancer cells (Ferraiuolo, et 
al., 2017) but this pathway regulation had never been shown in normal mammary cells. We 
suspect that Spy1-mediated invasion is MEK- and ERK1/2-dependent, but migration is 
only dependent on ERK signaling based on our results where ERK1/2 small molecule 




inhibitors had no statistical effect on migration. Although, there was an observable 
decrease so this needs to be evaluated further to make a definitive conclusion.  
The complexity of ERK1/2 signaling in normal development and cancer biology 
makes it a daunting task to try to dissect the direct upstream and downstream regulators in 
Spy1 mediated invasion and migration and because we see differences in regulation of 
invasion versus migration it is even more complex. More work needs to be completed to 
verify the mechanism of ERK1/2 activation by Spy1.      
Conclusion 
Overall this work has been a study of inflammatory and metastatic processes in breast 
cancer treatment and progression. Although, much more work is needed, I have shown that 
the long-term use of immunosuppressants, in breast cancer patients and other disease 
management, needs to be re-evaluated to determine if the detrimental side effects of the 
current immunosuppressants out-weigh the effectiveness of treatment. I introduced Spy1 
as a mediator of cell invasion and migration in normal and breast cancer cells. My hope is 
that collectively, this work will contribute to the advancement of breast cancer research so 
that in the future, protocols for breast cancer with distant metastases will include more than 
palliative treatment and care, which is the current recommended protocol as reported by 
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